

# 2024 Emergency-Clinical Performance Registry (E-CPR) and Hospital-Clinical Performance Registry (H-CPR) Measure Specifications Manual

Measure #	Measure Title
<a href="#"><u>ECPR39</u></a>	<a href="#"><u>Avoid Head CT for Patients with Uncomplicated Syncope</u></a>
<a href="#"><u>ECPR46</u></a>	<a href="#"><u>Avoidance of Opiate Prescriptions for Low Back Pain or Migraines</u></a>
<a href="#"><u>ECPR50</u></a>	<a href="#"><u>Door to Diagnostic Evaluation by a Provider – Urgent Care Patients</u></a>
<a href="#"><u>ECPR51</u></a>	<a href="#"><u>Discharge Prescription of Naloxone after Opioid Poisoning or Overdose</u></a>
<a href="#"><u>ECPR52</u></a>	<a href="#"><u>Appropriate Treatment of Psychosis and Agitation in the Emergency Department</u></a>
<a href="#"><u>ECPR55</u></a>	<a href="#"><u>Avoidance of Long-Acting (LA) or Extended-Release (ER) Opiate Prescriptions and Opiate Prescriptions for Greater Than 3 Days Duration for Acute Pain</u></a>
<a href="#"><u>ECPR56</u></a>	<a href="#"><u>Opioid Withdrawal: Initiation of Medication-Assisted Treatment (MAT) and Referral to Outpatient Opioid Treatment</u></a>
<a href="#"><u>ECPR58</u></a>	<a href="#"><u>Patient-Reported Understanding of Discharge Diagnosis and Plan of Care</u></a>
<a href="#"><u>ECPR59</u></a>	<a href="#"><u>Patient Reported Trust in Provider</u></a>
<a href="#"><u>APP A</u></a>	<a href="#"><u>Appendix A: Opioid Medications</u></a>
<a href="#"><u>APP B</u></a>	<a href="#"><u>Appendix B: ICD-10 diagnosis codes for pain, strains, sprains, lacerations, open wounds and fractures</u></a>
<a href="#"><u>HCPR20</u></a>	<a href="#"><u>Clostridium Difficile – Risk Assessment and Plan of Care</u></a>
<a href="#"><u>HCPR23</u></a>	<a href="#"><u>Avoidance of Echocardiogram and Carotid Ultrasound for Syncope</u></a>
<a href="#"><u>HCPR24</u></a>	<a href="#"><u>Appropriate Utilization of Vancomycin for Cellulitis</u></a>
<a href="#"><u>HCPR25</u></a>	<a href="#"><u>Physician’s Orders for Life-Sustaining Treatment (POLST) Form</u></a>
<a href="#"><u>HCPR26</u></a>	<a href="#"><u>Point-of-Care Ultrasound: Evaluation for Pneumothorax after Central Venous Catheter (CVC) Placement</u></a>
<a href="#"><u>HCPR27</u></a>	<a href="#"><u>Heart Failure (HF): SGLT-2 Inhibitor Therapy for Left Ventricular Systolic Dysfunction (LVSD)</u></a>

## **E-CPR (Emergency – Clinical Performance Registry) Measure #39**

*Referenced Choosing Wisely, Emergency Medicine Campaign Measure #6*

**Measure Title:** Avoid Head CT for Patients with Uncomplicated Syncope

**Inverse Measure:** No

**Measure Description:** Percentage of Adult Syncope Patients Who Did Not Receive a Head CT Scan Ordered by the Provider

**National Quality Strategy Domain:** Efficiency and Cost Reduction

**Care Setting:** Emergency Department and Services;  
Ambulatory Care; Ambulatory Care: Hospital; Ambulatory Care: Clinician Office/Clinic; Ambulatory Care: Urgent Care;  
Hospital; Hospital Inpatient; Hospital Outpatient; Outpatient Services

**Published Specialty:** Emergency Medicine; Urgent Care; Hospitalist

**Telehealth:** Yes

**Type of Measure:** Process, High Priority

**High Priority Type:** Appropriate Use

**Meaningful Measure Area:** Appropriate Use of Healthcare

**Current Clinical Guideline:** This measure reflects the best practice cited by the Choosing Wisely Campaign (American Board of Internal Medicine Foundation)

**Published Clinical Category:** Syncope

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Syncope Patients Who Did Not Have a Head CT Ordered by the Provider

Numerator Options

- **Performance Met (VE250):** Patients who did not have a head CT ordered.

**2024 Measures Specifications**

*Updated 2023.12.20*

- **Medical Performance Exclusion (Denominator Exception) (VE251):** Patients who did have a head CT ordered for medical reason documented by the eligible professional (i.e., Seizure; alcohol/drug intoxication; vomiting; altered mental status; abnormal neurologic exam; concern for intracranial injury/hemorrhage, stroke, or mass lesion).
- **Performance Not Met (VE252):** Patients who did have a head CT ordered, reason not given.

**Numerator Exclusions:** None

**Denominator:**

- Any patient ≥18 years of age evaluated by the Eligible Professional in the Emergency Department, Urgent Care Clinic, Inpatient or Observation Status settings (E/M Codes 99202-99205, 99212-99215, 99221-99223, 99231-99233, 99234-99236, 99238, 99239, 99281-99285, & 99291-99292 AND Place of Service Indicator: 02, 11, 19, 20, 21, 22 or 23 OR equivalent in standardized code sets) PLUS
- Diagnosis of Syncope:
  - **ICD-10:** R55
- Transferred, eloped or AMA patients are excluded (**V0700**)

**Denominator Exclusions:** None

**Rationale:**

(Referenced Choosing Wisely, Emergency Medicine Campaign Measure #6)

Syncope (passing out or fainting) or near syncope (lightheadedness or almost passing out) is a common reason for visiting an emergency department or urgent care clinic and most episodes are not serious. Many tests may be ordered to identify the cause of such episodes. However, some diagnostic tests for syncope should not be routinely ordered, and the decision to order any tests should be guided by information obtained from the patient’s history or physical examination. CT scans are expensive, and may unnecessarily expose patients to radiation. If a head injury is associated with a syncopal episode, then a CT scan of the brain may be indicated. In addition, if there were symptoms of a stroke (i.e., headache, garbled speech, weakness in one arm or leg, trouble walking or confusion) before or after a syncopal episode, a CT scan may be indicated. However, in the absence of head injury or signs of a stroke, a CT scan of the brain should not be routinely ordered. Recent studies show that there continues to be overutilization of neurological studies such as CT scans for patients with syncope, with little clinical benefit. In one study, only 6.4% of syncope patients who received head CTs had acutely abnormal findings (Mitsunaga, 2015). In a systematic review of studies on imaging for syncope, head CTs were the most common imaging test performed, and of those CTs performed, only 1.2% provided new diagnostic information. (Pournazari, 2017)

"The 2009 ESC guidelines recommended neurologic referral in patients in whom transient loss of consciousness is suspected to be epilepsy rather than syncope. In addition, neurologic referral to evaluate the underlying disease is indicated when syncope is due to autonomic failure. An EEG or carotid Doppler ultrasound study, computed tomography, or magnetic resonance imaging is not recommended unless a non-syncopal cause of transient loss of consciousness is suspected."

"Neurologic tests, including electroencephalogram (EEG), brain computed tomography scan, brain magnetic resonance imaging, and carotid Doppler ultrasound, are frequently obtained in patients with syncope. In one review of 649 patients, 53 percent had at least one neurologic test. However, such testing was rarely useful."

### **Selected References:**

- American College of Emergency Physicians (ACEP) and Choosing Wisely Campaign
- Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), Moya A, et al. Guidelines for the diagnosis and management of syncope. *Eur Heart J.* 2009;30(21):2631
- Mitsunaga M, Cho G. Head CT scans in the emergency department for syncope and dizziness. *Am Roentgen.* 2015;204:24-28.
- Pournazari P, Oqab Z, Sheldon R. Diagnostic value of neurological studies in diagnosing syncope: A systematic review. *Can J Cardiology.* 2017;33(12):1604-1610.
- Gallagher EJ. Hospitalization for fainting: high stakes, low yield. *Ann Emerg Med.* 1997 Apr;29(4):540-2.
- Pires LA, Ganji JR, Jarandila R, Steele R. Diagnostic patterns and temporal trends in the evaluation of adult patients hospitalized with syncope. *Arch Intern Med.* 2001Aug 13-27;161:1889-95.
- Giglio P, Bednarczyk EM, Weiss K, Bakshi R. Syncope and head CT scans in the emergency department. *Emerg Radiol.* 2005 Dec;12(1-2):44-6.
- Shukla GJ. Cardiology patient page. Syncope. *Circulation.* 2006 Apr 25;113(16):e715-7.
- Grossman SA, Fischer C, Bar JL, Lipsitz LA, Mottley L, Sands K, Thompson S, Zimetbaum P, Shapiro NI. The yield of head CT in syncope: a pilot study. *Intern Emerg Med.* 2007 Mar;2(1):46-9.
- Mendu ML, McAvay G, Lampert R, Stoehr J, Tinetti ME. Yield of diagnostic tests in evaluating syncopal episodes in older patients. *Arch Intern Med.* 2009 Jul 27;169(14):1299-305.

## **E-CPR (Emergency – Clinical Performance Registry) Measure #46**

**Measure Title:** Avoidance of Opiate Prescriptions for Low Back Pain or Migraines

**Inverse Measure:** No

**Measure Description:** Percentage of Patients with Low Back Pain and/or Migraines Who Were Not Prescribed an Opiate

**National Quality Strategy Domain:** Effective Clinical Care

**Care Setting:** Ambulatory Care; Ambulatory Care: Clinician Office/Clinic; Ambulatory Care: Urgent Care; Ambulatory Care: Clinician Office/Clinic; Outpatient Services; Emergency Department and Services; Hospital; Hospital Outpatient

**Published Specialty:** Emergency Medicine; Family Medicine; Internal Medicine; Primary Care; Urgent Care

**Telehealth:** Yes

**Type of Measure:** Process, High Priority

**High Priority Type:** Opioid-Related

**Meaningful Measure Area:** Prevention and Treatment of Opioid and Substance Use Disorders

**Current Clinical Guideline:** This measure is derived from recommendations for safe opioid prescribing from the CDC, American College of Emergency Physicians, and multiple other medical and state agencies.

**Published Clinical Category:** Opioid Management

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS; MIPS Value Pathway

**Numerator:** Patients who were not prescribed an opiate (see [Appendix A](#) for list of opioid medications)

Numerator Options:

- **Performance Met (VE263):** Opiate not prescribed at discharge.
- **Medical Performance Exclusion (Denominator Exception) (VE264):** Opiate prescribed for medical reason documented by the Eligible Professional (i.e., suspected or diagnosed herniated disk, fracture, sciatica, radiculopathy)

- **Performance Not Met (VE265):** Opiate prescribed, reason not specified.

**Numerator Exclusions:** None

**Denominator:**

- Any patient ≥ 18 years of age evaluated by the Eligible Professional in Emergency Department, Urgent Care Clinic, or Outpatient Clinic settings (E/M Codes 99202-99205, 99212-99215, 99281-99285, 99291-99292 AND Place of Service Indicator: 02,10, 11, 19, 20, 22 or 23 or equivalent in standardized code sets) PLUS
- Diagnosis of low back pain OR
  - ICD-10: M54.50, M54.51, M54.59
- Diagnosis of migraine PLUS
  - ICD-10: G43.001, G43.009, G43.011, G43.019, G43.101, G43.109, G43.111, G43.119, G43.401, G43.409, G43.411, G43.419, G43.501, G43.509, G43.511, G43.519, G43.601, G43.609, G43.611, G43.619, G43.701, G43.709, G43.711, G43.719, G43.A0, G43.A1, G43.B0, G43.B1, G43.C0, G43.C1, G43.D0, G43.D1, G43.801, G43.809, G43.811, G43.819, G43.821, G43.829, G43.831, G43.839, G43.901, G43.909, G43.911, G43.919, G43.E01, G43.E09, G43.E11, G43.E19
- Disposition of Discharged

**Denominator Exclusions:** Patients with active cancer, palliative care, end-of-life care (**V0709**)

**Rationale:**

Low back pain and migraine headaches are two conditions that frequently present to the hospital for acute care and are conditions for which narcotic pain medication is not indicated according to national guidelines.

Low back pain

Acute low back pain is a common chief complaint in the Emergency Department. Opioids are frequently prescribed, expected, or requested for such presentations. (Friedman 2012, Friedman 2010) The opioid analgesics most commonly prescribed for low back pain, hydrocodone and oxycodone products, are also those most prevalent in a Government Accountability Office study of frequently abused drugs.(GAO 2011) Low back pain as a presenting complaint was also observed in a recent study to be associated with patients at higher risk for opioid abuse. (Sullivan 2010) Two meta-analyses have demonstrated no superiority for opioids over other therapies for treatment of acute low back pain, (MacIntosh 2011, Roelofs 2008) and several groups have recommended against use of opioids as first-line therapy for treatment of this problem. (Chou 2007, ACOEM 2007) A retrospective study found that workers with acute low back injury and worker’s compensation claims who were treated with prescription opioids within 6 weeks of acute injury for more than 7 days had a significantly higher risk for long-term disability. (Franklin 2008)

Several non-opioid pharmacologic therapies (including acetaminophen, NSAIDs, and selected antidepressants and anticonvulsants) are effective for chronic pain. In particular, acetaminophen and NSAIDs can be useful for arthritis and low back pain. (Dowell 2016) Non-opioid pharmacologic therapies are not generally associated

with substance use disorder. (Jones 2013)

Many non-pharmacologic therapies, including physical therapy, weight loss and certain interventional procedures can ameliorate low back pain. There is high-quality evidence that exercise therapy (a prominent modality in physical therapy) reduces pain and improves function. (Hayden 2005) Multimodal therapies and multidisciplinary biopsychosocial rehabilitation approaches can reduce long-term pain and disability compared with usual care and compared with physical treatments (e.g., exercise) alone. Non-pharmacologic therapy and non-opioid pharmacologic therapy can be combined, as appropriate, to provide greater benefits to patients in improving pain and function.

### Migraine headaches

According to guidelines released by the American Academy of Neurology and the American Headache Society, narcotic pain medications are not included as first-line treatments for migraine headaches. Instead, the following medications are established as effective and should be offered for migraine treatment prevention: (Silberstein 2012, Holland 2012)

- Antiepileptic drugs (AEDs): divalproex sodium, sodium valproate, topiramate
- $\beta$ -Blockers: metoprolol, propranolol, timolol, atenolol, and nadolol
- Triptans: frovatriptan, naratriptan, and zolmitriptan for short-term MAMs prevention
- Antidepressants: amitriptyline, venlafaxine (but not SSRIs)
- NSAIDs: fenoprofen, ibuprofen, ketoprofen, naproxen, naproxen sodium

In 2016, the American Headache Society released guidelines for the management of adults with acute migraine in the emergency department. (Orr 2016, Silberstein 2016) They recommend intravenous metoclopramide, intravenous prochlorperazine, and subcutaneous sumatriptan to treat these patients. Dexamethasone should be offered to these patients to prevent recurrence of headache, and they noted that opioids should be avoided (Orr 2016, Silberstein 2016). Although narcotics remain the most frequently administered medication for patients with migraine and for ED patients with headache, evidence suggests that they are potentially ineffective, and their use may lead to more prolonged ED stays. (Sahai-Srivastava 2008, Tornabene 2009)

In 2017, HHS declared the opioid crisis a national public health emergency, in no small part due to misuse of opioid prescription drugs. (GAO, 2018) Reducing unnecessary opioid prescriptions is one key strategy for limiting potential of misuse. Overprescribing continues to be an opportunity for improvement. One research survey assessed headache types, comorbid conditions, and whether they had ever been prescribed opioids. (Minen 2015) With a predominant diagnosis of migraine (83.9%), more than half of the patients reported having been prescribed an opioid (54.8%). About one fifth were taking opioids (19.4%) at the time of completing the survey, and one quarter of patients reported taking opioids for more than 2 years (24.6%). The reason most frequently cited for stopping opioids was that they saw a new doctor who would not prescribe them (29.4%). The physician specialty most frequently cited as being the first prescriber for opioids was emergency medicine (20.2%), followed by family doctors and neurologists at 17.7% each. (Minen 2015)

To assess the extent of and factors associated with geographic variation in early opioid prescribing for acute, work-related, low back pain (LBP), national workers compensation administrative data filed from 2002-2003 was analyzed in a study. Of over 8,000 low back pain claimants, 21.3% received at least one early opioid prescription. Significant variation in prescribing practices was found between states was found, from 6% to

53%. Individual-level patient factors, including severity, explained only a small portion of the geographic variability. (Webster 2009)

### **Selected References:**

- American College of Occupational and Environmental Medicine. Low Back Disorders. Occupational Medicine Practice Guidelines: Evaluation and Management of Common Health Problems and Functional Recovery in Workers. 2nd ed. Elk Grove Village, IL; 2007.
- American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. *J Am Geriatr Soc* 2009;57:1331–46.
- Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. *Spine* 2014;39:556–63.
- Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. *Ann Intern Med*. 2007;147:478-491.
- Chou R, Qaseem A, Snow V, et al.; Clinical Efficacy Assessment Subcommittee of the American College of Physicians; American College of Physicians; American Pain Society Low Back Pain Guidelines Panel. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. *Ann Intern Med* 2007;147:478–91.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. *MMWR Recomm Rep* 2022;71(No. RR-3):1–95. <https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm>
- Food and Drug Administration. FDA drug safety communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2015. <http://www.fda.gov/Drugs/DrugSafety/ucm451800.htm>
- Franklin GM, Stover BD, Turner JA, et al. Early opioid prescription and subsequent disability among workers with back injuries. *Spine*. 2008;33:199-204.
- Friedman BW, Chilstrom M, Bijur PE, et al. Diagnostic testing and treatment of low back pain in US emergency departments. A national perspective. *Spine*. 2010;35:E1406-E1411.
- Friedman BW, O’Mahony S, Mulvey L, et al. One-week and 3-month outcomes after an emergency department visit for undifferentiated musculoskeletal low back pain. *Ann Emerg Med*. 2012;59:128-133.
- Friedman BW, Solorzano C, Esses D, Xia S, Hochberg M, Dua N, et al. Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. *Ann Emerg Med*. 2010 Jul. 56(1):7-17.
- Hayden JA, van Tulder MW, Malmivaara A, Koes BW. Exercise therapy for treatment of non-specific low back pain. *Cochrane Database Syst Rev* 2005;3:CD000335.
- Hochberg MC, Altman RD, April KT, et al. ; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)* 2012;64:465–74.
- Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012 Apr 24. 78 (17):1346-53.
- Hooten WM, Timming R, Belgrade M, et al. Assessment and management of chronic pain. Bloomington, MN: Institute for Clinical Systems Improvement; 2013. [https://www.icsi.org/\\_asset/bw798b/](https://www.icsi.org/_asset/bw798b/)



ChronicPain.pdf

- Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. *JAMA* 2013;309:657–9. <http://dx.doi.org/10.1001/jama.2013.272>
- Mannion AF, Müntener M, Taimela S, Dvorak J. A randomized clinical trial of three active therapies for chronic low back pain. *Spine (Phila Pa 1976)* 1999;24:2435–48. <http://dx.doi.org/10.1097/00007632-199912010-00004>
- McIntosh G, Hall H. Low back pain (acute). *Clin Evid (Online)*. 2011;05:1102.
- Minen MT, Lindberg K, Wells RE, Suzuki J, Grudzen C, Balcer L, Loder E. Survey of Opioid and Barbiturate Prescriptions in Patients Attending a Tertiary Care Headache Center. *Headache*. 2015 Oct;55(9):1183-91. Epub 2015 Aug 28.
- Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, et al. Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. *Headache*. 2016 Jun. 56 (6):911-40.
- Roelofs PDDM, Deyo RA, Koes BW, et al. Non-steroidal anti-inflammatory drugs for low back pain. *Cochrane Database Syst Rev*. 2008;(1):CD000396. doi:10.1002/14651858. CD000396.pub3.
- Sahai-Srivastava S, Desai P, Zheng L. Analysis of headache management in a busy emergency room in the United States. *Headache*. 2008 Jun. 48(6):931-8.
- Silberstein S. The Management of Adults With Acute Migraine in the Emergency Department. *Headache*. 2016 Jun. 56 (6):907-8.
- Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012 Apr 24. 78 (17):1337-45.
- Sullivan MD, Edlund MJ, Fan MY, et al. Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and Medicaid insurance plans: the TROUP Study. *Pain*. 2010;150:332-339.
- Tornabene SV, Deutsch R, Davis DP, Chan TC, Vilke GM. Evaluating the use and timing of opioids for the treatment of migraine headaches in the emergency department. *J Emerg Med*. 2009 May. 36(4):333-7.
- Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. *BMJ* 2011;342:c7086.
- United States Government Accountability Office. Instances of Questionable Access to Prescription Drugs. GAO-11-699. Washington, DC: Government Accountability Office;2011.
- United States Government Accountability Office. Opioid Crisis: Status of Public Health Emergency Authorities;2018.
- Volinn E, Fargo JD, Fine PG. Opioid therapy for nonspecific low back pain and the outcome of chronic work loss. *Pain*. 2009; 142:194-201.
- Webster BS, Cifuentes M, Verma S, Pransky G. Geographic variation in opioid prescribing for acute, work-related, low back pain and associated factors: a multilevel analysis. *Am J Ind Med*. 2009 Feb;52(2):162-71.

## **APPENDIX A. Opioid Medications**

<b>Generic</b>	<b>Brand Name</b>
alfentanil	Alfenta®
buprenorphine	Belbuca®, Bunavail, Buprenex®, Butrans®
butorphanol	No brand name currently marketed
codeine	Fioricet® w/ codeine, Fiorinal® w/ codeine, Soma® Compound w/ codeine, Tylenol w/ codeine, Prometh® VC w/ codeine (cough), Triacin®-C (cough), Tuzistra®-XR (cough)
dihydrocodeine	Synalgos-DC
fentanyl	Abstral®, Actiq®, Duragesic®, Fentora®, Ionsys®, Lazanda®, Onsolis®, Sublimaze®, Subsys®
hydrocodone	Anexsia®, Hysingla® ER, Lortab®, Lorcet®, Norco®, Reprexain®, Vicodin®, Vicoprofen®, Zohydro® ER, Flowtuss® (cough), Hycofenix® (cough), Obredon® (cough), Rezira® (cough), Tussicaps® (cough), Tussigon® (cough), Tussionex® Pennkinetic® (cough), Vituz® (cough), Zutripro® (cough)
hydromorphone	Dilaudid®, Dilaudid®-HP, Exalgo®
meperidine	Demerol®
methadone	Dolophine®, Methadose®
morphine	Astramorph® PF, Avinza® Duramorph® PF, Embeda®, Infumorph®, Kadian®, Morphabond®, MS Contin®, Roxanol®
oxycodone	Oxaydo®, Oxycet®, Oxycotin®, Percocet®, Percodan®, Roxicet®, Roxicodone®, Tylox® Xartemis® XR
oxymorphone	Opana®, Opana ER
pentazocine	Talwin®
remifentanil	Ultiva®
sufentanil	Sufenta®
tapentadol	Palexia®, Nucynta®, Nucynta ER
tramadol	Conzip®, Ultracet®, Ultram®, Ultram ER

## **E-CPR (Emergency – Clinical Performance Registry) Measure #50**

**Measure Title:** Door to Diagnostic Evaluation by a Provider Within 30 Minutes – Urgent Care Patients

**Inverse Measure:** No

**Measure Description:** Percentage of Outpatient Medicine Patients Who Made Provider Contact Within 30 Minutes of Urgent Care Clinic (UCC) Arrival

**National Quality Strategy Domain:** Patient Safety

**Care Setting:** Ambulatory Care: Urgent Care

**Published Specialty:** Urgent Care

**Telehealth:** Yes

**Type of Measure:** Process, High Priority

**High Priority Type:** Patient Safety

**Meaningful Measure Area:** Preventable Healthcare Harm

**Current Clinical Guideline:** This measure is derived from the CMS OQR OP-20 measure and extrapolated to the urgent care setting.

**Published Clinical Category:** Urgent Care Efficiency

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Urgent Care Patients Who Made Provider (MD/DO/PA/NP) Contact Within 30 Minutes of Urgent Care Clinic Arrival

- Definition of Arrival Time: The earliest documented time the patient arrived at the Urgent Care Clinic
- Definition of Provider Contact Time: The time of the first direct, personal exchange between an Urgent Care patient and the Eligible Professional

**Numerator Exclusions:** None

**Denominator:** Any Patient Evaluated by the Eligible Professional (MD/DO/PA/NP) in the Urgent Care Clinic (E/M Codes 99202-99205 & 99212-99215 AND Place of Service Indicator: 02, 11, 19, 20 or 22 OR equivalent in

***2024 Measures Specifications***

*Updated 2023.12.20*

standardized code sets)

**Denominator Exclusions:** None

**Rationale:**

In recent years, patients are increasingly accessing urgent care centers for urgent or episodic care, and the number of urgent care centers has markedly increased in the past several years. With continued growth, increased clinician focus on wait times in the urgent care setting improves access to treatment and increase quality of care. Reducing this time improves access to care tailored to patient needs, increases the capability to provide additional treatment or divert patients quickly to emergency departments (EDs) as necessary, and improves patient satisfaction.

Timely access to urgent care is especially pertinent as EDs have continued to experience significant overcrowding and prolonged wait times in recent times, and an estimated 27% of ED visits could be treated in the urgent care setting. With the increased number of urgent care clinics in recent years, urgent care clinics have become an increasingly viable option for patients seeking immediate treatment, imaging and testing for lower-acuity conditions who have traditionally sought care at emergency departments.

**Selected References:**

- Urgent Care Association of America. 2017 Urgent Care Benchmarking Report Summary. 2017.
- Urgent Care Association of America. 2016 Urgent Care Benchmarking Report Summary. 2016.
- Weinick RM, Burns RM, Mehrotra A. Many Emergency Department Visits Could Be Managed At Urgent Care Centers And Retail Clinics. *Health Aff.* 2010; 29(9):1630-1636.
- Derlet RW, Richards JR. Emergency department overcrowding in Florida, New York, and Texas. *South Med J.* 2002; 95:846-9.
- Derlet RW, Richards JR. Overcrowding in the nation's emergency departments: complex causes and disturbing effects. *Ann Emerg Med.* 2000; 35:63-8.
- Fatovich DM, Hirsch RL. Entry overload, emergency department overcrowding, and ambulance bypass. *Emerg Med J.* 2003; 20:406-9.
- Institute of Medicine of the National Academies. Future of emergency care: Hospital-based emergency care at the breaking point. *The National Academies Press* 2006.
- Kyriacou DN, Ricketts V, Dyne PL, McCollough MD, Talan DA. A 5-year time study analysis of emergency department patient care efficiency. *Ann Emerg Med.* 1999; 34:326-35.
- Pines JM, et al. Emergency department crowding is associated with poor care for patients with severe pain. *Ann Emerg Med.* 2008; 51:6-7.
- Siegel B, et al. Enhancing work flow to reduce crowding. *Jt Comm J Qual Patient Saf.* 2007; 33 (11 Suppl):57-67.
- Trzeciak S, Rivers EP. Emergency department overcrowding in the United States: an emerging threat to patient safety and public health. *Emerg Med J.* 2003; 20:402.

## **E-CPR (Emergency – Clinical Performance Registry) Measure #51**

**Measure Title:** Discharge Prescription of Naloxone after Opioid Poisoning or Overdose

**Inverse Measure:** No

**Measure Description:** Percentage of Opioid Poisoning or Overdose Patients Presenting to An Acute Care Facility Who Were Prescribed Naloxone at Discharge

**National Quality Strategy Domain:** Effective Clinical Care

**Care Setting:** Emergency Department and Services; Hospital; Hospital Inpatient

**Published Specialty:** Emergency Medicine; Hospitalist.

**Telehealth:** Yes

**Type of Measure:** Process, High Priority

**High Priority Type:** Opioid-Related

**Meaningful Measure Area:** Prevention and Treatment of Opioid and Substance Use Disorders

**Current Clinical Guideline:** Numerous organizations, including the American Medical Association and American Society of Addiction Medicine, recommend increased access to Naloxone for patients who are at high risk to reverse the effects and reduce the chance of death in the event of an opioid overdose, which includes expanded prescribing practices by clinicians.

**Published Clinical Category:** Opioid Management

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Patients Who Were Prescribed Naloxone AND Educated About Utilization at Discharge

- **Performance Met (VE269):** Naloxone was prescribed at discharge AND patient was educated about use.
- **Medical Performance Exclusion (Denominator Exception) (VE270):** Naloxone was not prescribed at discharge due to medical reasons such as allergy.
- **Performance Not Met (VE271):** Naloxone medication was not prescribed at discharge OR patient was not educated about use.
- **NOTE: Distribution of Naloxone to patient at discharge is also acceptable in lieu of Naloxone prescription**

**Numerator Exclusions:** None

**Denominator:**

- Any patient evaluated by the Eligible Professional in acute care setting (E/M Codes 99234-99236, 99238-99239, 99281-99285 AND Place of Service indicator 02, 21, 22 or 23 OR equivalent in standardized code sets) PLUS
- Diagnosis of opioid poisoning from heroin, methadone, morphine, opium, codeine, hydrocodone, or another opioid substance
  - ICD-10: T40.0X1A, T40.0X1D, T40.0X1S, T40.0X2A, T40.0X2D, T40.0X2S, T40.0X3A, T40.0X3D, T40.0X3S, T40.0X4A, T40.0X4D, T40.0X4S, T40.1X1A, T40.1X1D, T40.1X1S, T40.1X2A, T40.1X2D, T40.1X2S, T40.1X3A, T40.1X3D, T40.1X3S, T40.1X4A, T40.1X4D, T40.1X4S, T40.2X1A, T40.2X1D, T40.2X1S, T40.2X2A, T40.2X2D, T40.2X2S, T40.2X3A, T40.2X3D, T40.2X3S, T40.2X4A, T40.2X4D, T40.2X4S, T40.3X1A, T40.3X1D, T40.3X1S, T40.3X2A, T40.3X2D, T40.3X2S, T40.3X3A, T40.3X3D, T40.3X3S, T40.3X4A, T40.3X4D, T40.3X4S, , T40.411A, T40.411D, T40.411S, T40.412A, T40.412D, T40.412S, T40.413A, T40.413D, T40.413S, T40.414A, T40.414D, T40.414S, T40.421A, T40.421D, T40.421S, T40.422A, T40.422D, T40.422S, T40.423A, T40.423D, T40.423S, T40.424A, T40.424D, T40.424S, T40.491A, T40.491D, T40.491S, T40.492A, T40.492D, T40.492S, T40.493A, T40.493D, T40.493S, T40.494A, T40.494D, T40.494S, T40.601A, T40.601D, T40.601S, T40.602A, T40.602D, T40.602S, T40.603A, T40.603D, T40.603S, T40.604A, T40.604D, T40.604S, T40.691A, T40.691D, T40.691S, T40.692A, T40.692D, T40.692S, T40.693A, T40.693D, T40.693S, T40.694A, T40.694D, T40.694S
- Disposition of Discharged
- Transferred, eloped or AMA patients are excluded (**V0700**)

**Denominator Exclusions:** None

**Rationale:**

The opioid epidemic in the United States claims hundreds of lives every day. One of medicine’s best tools against this epidemic is Naloxone. Naloxone has proven to be the most effective method for reversing an opioid overdose in patients of all characteristics and has been shown to greatly reduce the chance of fatality. Naloxone is a non-selective, short-acting opioid receptor antagonist used to treat opioid induced respiratory depression. It is safe, has no addictive potential, and has mild side effects. The use of naloxone has been consistently recommended and promoted by numerous health organizations including the American Medical Association. Increasing the availability of Naloxone among the public, law enforcement, and community organizations is advocated by many organizations including the American Society of Addiction Medicine and is a priority of numerous states and federal health agencies. Despite these recommendations, a survey of opioid-related policies in New England emergency departments found that only 12% of departments would prescribe naloxone for patients at risk of opioid overdose after discharge. Promoting the prescription of Naloxone for patients discharged after an opioid overdose will ensure that the chance of fatality across all patient populations is significantly reduced.

**Selected References:**

- Bird, S. M., McAuley, A., Perry, S., & Hunter, C. (2016). Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006–10) versus after (2011–13) comparison. *Addiction*, 111(5), 883-891.
- CMS finalizes measures to help combat opioid crisis. (2018, April 16). Retrieved from <https://www.the-hospitalist.org/hospitalist/article/162747/pain/cms-finalizes-measures-help-combat-opioid-crisis/page/0/3>
- Dorp, E. L., Yassen, A., & Dahan, A. (2007). Naloxone treatment in opioid addiction: The risks and benefits. *Expert Opinion on Drug Safety*, 6(2), 125-132. doi:10.1517/14740338.6.2.125
- Dunne, R. B. (2018). Prescribing naloxone for opioid overdose intervention. *Pain Management*, 8(3).
- Dwyer, K., Walley, A. Y., Langlois, B. K., Mitchell, P. M., Nelson, K. P., Cromwell, J., & Bernstein, E. (2015). Opioid education and nasal naloxone rescue kits in the emergency department. *Western Journal of Emergency Medicine*, 16(3), 381.
- Help save lives: Co-prescribe naloxone to patients at risk of overdose. (2017). AMA Opioid Task Force. Retrieved from <https://www.end-opioid-epidemic.org/wp-content/uploads/2017/08/AMA-Opioid-Task-Force-naloxone-one-pager-updated-August-2017-FINAL-1.pdf>
- Kestler, A., Buxton, J., Meckling, G., Giesler, A., Lee, M., Fuller, K., Scheuermeyer, F. (2017). Factors associated with participation in an emergency department–based take-home naloxone program for at-risk opioid users. *Annals of emergency medicine*, 69(3), 340-346.
- Kmeic, J., DO. (n.d.). Module 4: Special Aspects of the Treatment of Substance Use Disorders. Retrieved June 13, 2018, from <http://pcssnow.org/wp-content/uploads/2016/08/Prescribing-Nalxone-to-Patients-for-Overdose-Reversal.pdf>
- Kounang, N. (2017, October 30). Naloxone reverses 93% of overdoses. Retrieved from <https://www.cnn.com/2017/10/30/health/naloxone-reversal-success-study/index.html>
- Public Policy Statement on the Use of Naloxone for the Prevention of Opioid Overdose Deaths. (n.d.). Retrieved June 13, 2018, from <https://www.asam.org/docs/default-source/public-policy-statements/use-of-naloxone-for-the-prevention-of-opioid-overdose-deaths-final.pdf?sfvrsn=4>  
American Society of Addiction Medicine
- Reardon, J. M., Harmon, K. J., Schult, G. C., Staton, C. A., & Waller, A. E. (2016). Use of diagnosis codes for detection of clinically significant opioid poisoning in the emergency department: A retrospective analysis of a surveillance case definition. *BMC emergency medicine*, 16(1), 11.
- Wong, F., Edwards, C. J., Jarrell, D. H., & Patanwala, A. E. (2018). Comparison of lower-dose versus higher-dose intravenous naloxone on time to recurrence of opioid toxicity in the emergency department. *Clinical Toxicology*, 1-6.

## **E-CPR (Emergency – Clinical Performance Registry) Measure #52**

**Measure Title:** Appropriate Treatment of Psychosis and Agitation in the Emergency Department

**Inverse Measure:** No

**Measure Description:** Percentage of Adult Patients With Psychosis or Agitation Who Were Ordered an Oral Antipsychotic Medication in the Emergency Department

**National Quality Strategy Domain:** Effective Clinical Care

**Care Setting:** Emergency Department and Services

**Published Specialty:** Emergency Medicine

**Telehealth:** Yes

**Type of Measure:** Process

**Meaningful Measure Area:** Prevention, Treatment and Management of Mental Health

**Current Clinical Guideline:** There is no specific clinical guideline; however, there is a growing body of evidence in the emergency psychiatry literature supporting early administration of antipsychotics for agitation and psychosis.

**Published Clinical Category:** Mental/Behavior Disorders

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Patients who were ordered at least one oral dose of a typical or atypical antipsychotic or an antipsychotic combination medication

**Definition (Qualifying Medications):**

- First Generation Antipsychotics
  - Chlorpromazine
  - Droperidol
  - Fluphenazine
  - Haloperidol
  - Loxapine
  - Molindone
  - Perphenazine
  - Pimozide



- Prochlorperazine
- Thioridazine
- Thiothixene
- Trifluoperazine
- Second Generation Antipsychotics
  - Aripiprazole
  - Asenapine
  - Clozapine
  - Olanzapine
  - Iloperidone
  - Lurasidone
  - Paliperidone
  - Quetiapine
  - Risperidone
  - Ziprasidone
  - Brexpiprazole (Rexulti)
  - Olanzapine and samidorphan (Lybalvi)
  - Lumateperone
  - Cariprazine
- Combination Antipsychotics
  - Olanzapine-Fluoxetine
  - Perphenazine-Amitriptyline

Numerator Options:

- **Performance Met (VE272):** Oral dose of a typical or atypical antipsychotic or an antipsychotic combination medication ordered.
- **Medical Performance Exclusion (Denominator Exception) (VE273):** Oral dose of a typical or atypical antipsychotic or an antipsychotic combination medication not ordered for medical reason documented by the eligible professional (e.g., patient refusal, inability to tolerate, allergy, intramuscular/intravenous route chosen due to aggressive behavior, or other documented medical reason).
- **Performance Not Met (VE274):** Oral dose of a typical or atypical antipsychotic or an antipsychotic combination medication not ordered, reason not specified.

**Numerator Exclusions:** None

**Denominator:**

- Any patient ≥ 18 years of age evaluated by the Eligible Professional in the Emergency Department (99281-99285 & 99291-99292 AND Place of Service Indicator: 02, 23 OR equivalent in standardized code sets) PLUS
- Emergency department length of stay of 4 hours or more PLUS

- Primary diagnosis of psychosis, psychotic disorder NOS, psychotic features, hallucinations, schizophrenia, schizoaffective disorder, agitation due to psychosis
  - ICD10: F06.0, F06.2, F10.150, F10.151, F10.159, F10.250, F10.251, F10.259, F10.950, F10.951, F10.959, F11.150, F11.151, F11.159, F11.250, F11.251, F11.259, F11.950, F11.951, F11.959, F12.150, F12.151, F12.159, F12.250, F12.251, F12.259, F12.950, F12.951, F12.959, F13.150, F13.151, F13.159, F13.250, F13.251, F13.259, F13.950, F13.951, F13.959, F14.150, F14.151, F14.159, F14.250, F14.251, F14.259, F14.950, F14.951, F14.959, F15.150, F15.151, F15.159, F15.250, F15.251, F15.259, F15.950, F15.951, F15.959, F16.150, F16.151, F16.159, F16.250, F16.251, F16.259, F16.950, F16.951, F16.959, F18.150, F18.151, F18.159, F18.250, F18.251, F18.259, F18.950, F18.951, F18.959, F19.150, F19.151, F19.159, F19.250, F19.251, F19.259, F19.950, F19.951, F19.959, F20.0, F20.1, F20.2, F20.3, F20.5, F20.81, F20.89, F20.9, F21, F23, F24, F25.0, F25.1, F25.8, F25.9, F28, F29, F30.2, F31.2, F31.5, F31.64, F32.3, F33.3, F53.1
- Eloped or AMA patients are excluded (**V0712**)

**Denominator Exclusions:** None

**Rationale:**

In the United States, there has been increased demand for Emergency Department (ED) psychiatric care but decreased availability of psychiatric resources and inpatient psychiatric beds. As a result, a national ED psychiatric boarding crisis has developed (Nolan et al, 2015; Parwani et al, 2018). Psychiatric patients are known to board in the ED for more prolonged periods of time relative to medical patients with averages of 7 to 34 hours (Zeller et al, 2014).

Patients that are boarded in Emergency Departments and awaiting definitive psychiatric evaluation suffer from delays in care and potential progression of their symptoms. The patients at greatest risk are those with acute agitation and psychosis, which are potentially dangerous conditions for the patients and the physicians and staff caring for them. Often, these patients eventually require chemical or physical restraints which may contribute to morbidity and mortality and further prolong their boarding stay (Gomez & Dopheide, 2016). Oral antipsychotic medications are known to be effective in treating active psychosis without the more profound sedating effects of parenteral (IM or IV) antipsychotics. Recent literature supports that ED patients would benefit from earlier administration of PO antipsychotics to promote earlier healing and recovery. Studies have indicated that the oral administration of antipsychotics is preferable and equally effective when compared to intravenous or intramuscular administration (Mullinax et al, 2017; Wilson et al, 2012; Yildiz et al, 2003). This practice would help to initiate earlier therapy for psychiatric patients and prevent unnecessary morbidity and mortality.

**Selected References:**

- Gomez S, Dopheide J. Antipsychotic Selection for Acute Agitation and Time to Repeat Use in a Psychiatric Emergency Department. *J Psychiatr Pract.* 2016 Nov; 22(6): 450-458.
- Mullinax S, Shokrane F, Wilson MP, et al. Oral Medication for Agitation of Psychiatric Origin: A Scoping Review of Randomized Controlled Trials. *J Emerg Med.* 2017 Oct; 53(4): 524-529.
- Nolan JM, Fee C, Cooper BA, Rankin SH, Blegen MA. Psychiatric boarding incidence, duration, and associated factors in United States emergency departments. *J Emerg Nurs* 2015;41:57– 64.

- Parwani V, Tinloy B, Ulrich A. Opening of Psychiatric Observation Unit Eases Boarding Crisis. Acad Emerg Med. 2018 Apr;25(4):456-460.
- Wilson MP, Pepper D, Currier GW, et al. The psychopharmacology of agitation: consensus statement of the American association of emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med. 2012 Feb; 13(1): 26-34.
- Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency setting. Emerg Med J. 2003 Jul; 20(4): 339-46.
- Zeller S, Calma N, Stone A. Effects of a dedicated regional psychiatric emergency service on boarding of psychiatric patients in area emergency departments. West J Emerg Med 2014;15:1– 6.

## **E-CPR (Emergency – Clinical Performance Registry) Measure #55**

**Measure Title:** Avoidance of Long-Acting (LA) or Extended-Release (ER) Opiate Prescriptions and Opiate Prescriptions for Greater Than 3 Days Duration for Acute Pain

**Inverse Measure:** No

**Measure Description:** Percentage of Adult Patients Who Were Prescribed an Opiate Who Were Not Prescribed a Long-Acting (LA) or Extended-Release (ER) Formulation and for Whom the Prescription Duration Was Not Greater than 3 days for Acute Pain

**National Quality Strategy Domain:** Effective Clinical Care

**Care Setting:** Ambulatory; Ambulatory: Urgent Care; Ambulatory Care: Hospital; Ambulatory Care: Clinician Office/Clinic; Emergency Department and Services; Hospital; Outpatient Services; Hospital Outpatient

**Published Specialty:** Emergency Medicine; Family Medicine; Internal Medicine; Primary Care; Urgent Care

**Telehealth:** Yes

**Type of Measure:** Process, High Priority

**High Priority Type:** Opioid-Related

**Meaningful Measure Area:** Prevention and Treatment of Opioid and Substance Use Disorders

**Current Clinical Guideline:** The CDC, American Academy of Emergency Medicine, Medical Board of California, Emergency Medicine Patient Safety Foundation, and multiple other organizations recommend against the use of long-acting opioids in the acute care setting and recommend opioids only if the severity of the pain warrants their use and only for short durations or in small quantities.

**Published Clinical Category:** Opioid Management

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Patients who were not prescribed a long-acting (LA) or extended-release (ER) opiate, and not prescribed any opiate ([see Appendix A for list of opioid medications](#)) prescription for greater than 3 days duration

Definition:

Long-Acting Opioid Drugs
<ul style="list-style-type: none"><li>• Arymo ER (morphine sulfate)</li><li>• Belbuca (buprenorphine)</li><li>• buprenorphine</li><li>• Butrans (transdermal buprenorphine)</li><li>• Dolophine (methadone hydrochloride)</li><li>• Duragesic (fentanyl transdermal system)</li><li>• Embeda (morphine sulfate and naltrexone hydrochloride)</li><li>• Exalgo (hydromorphone hydrochloride)</li><li>• fentanyl transdermal system</li><li>• hydrocodone bitartrate extended-release</li><li>• hydromorphone hydrochloride extended-release</li><li>• Hysingla ER (hydrocodone bitartrate)</li><li>• Kadian (morphine sulfate)</li><li>• methadone hydrochloride</li><li>• Methadose (methadone hydrochloride)</li><li>• Morphabond (morphine sulfate)</li><li>• morphine sulfate extended release</li><li>• MS Contin (morphine sulfate)</li><li>• Nucynta ER (tapentadol)</li><li>• Opana ER (oxymorphone hydrochloride)</li><li>• OxyContin (oxycodone hydrochloride)</li><li>• oxymorphone hydrochloride extended release</li><li>• Targiniq ER (oxycodone and naloxone hydrochloride)</li><li>• Troxyca ER (oxycodone hydrochloride and naloxone hydrochloride)</li><li>• Vantrela ER (hydrocodone bitartrate)</li><li>• Xtampza ER (oxycodone)</li><li>• Zohydro ER (hydrocodone)</li></ul>
<p><b>Source:</b> Adapted from FDA Approved Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting (ER/LA) Opioid Analgesics <a href="https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=RemsDetails.page&amp;REMS=17">https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=RemsDetails.page&amp;REMS=17</a></p>

Numerator Options:

- **Performance Met (VE266):** LA/ER formulation opiate not prescribed AND opiate not prescribed for greater than 3 days duration.
- **Medical Performance Exclusion (Denominator Exception) (VE267):** LA/ER formulation opiate or opiate prescribed for greater than 3 days duration due to terminal (late-stage) cancer, comfort care measures, palliative care, or coordinated plan of care for Medication Assisted Treatment (MAT)
- **Performance Not Met (VE268):** LA/ER formulation opiate prescribed OR opiate prescribed for greater than 3 days, reason not specified.

**Numerator Exclusions:** None

**Denominator:**

- Any patient  $\geq 18$  years of age evaluated by the Eligible Professional in Emergency Department, Urgent Care Clinic, or Outpatient Clinic settings (E/M Codes 99202-99205, 99212-99215, 99281-99285, 99291-99292 AND Place of Service Indicator: 02, 10, 11, 19, 20, 22 or 23 or equivalent in standardized code sets) PLUS

- Opiate prescribed (VE284) PLUS
- ICD-10 diagnosis codes for pain, strains, sprains, lacerations, open wounds and fractures ([see Appendix B](#) for codes) PLUS
- Disposition of Discharged

**Denominator Exclusions:** None

**Rationale:**

Drug overdose is now the leading cause of accidental deaths in the US, exceeding deaths due to motor vehicle accidents. A majority of those deaths involve prescription drugs. The diversion of opioid medications to non-medical uses has also contributed to the increased number of deaths. In 2015, prescription opioids and heroin killed over 33,000 people. The Centers for Disease Control and Prevention (CDC) estimates that, on average, 91 U. S. citizens die from an opioid overdose every day, and nearly half of these overdoses are caused by prescription drugs. Since 1999, the number of prescription opioids sold in the US and the number of prescription opioid-related deaths has quadrupled. The majority of prescription opioids used for nonmedical reasons are diverted from prescriptions originally written for therapeutic use. (Dowell CDC 2016) Injuries related to opioid medications are also occurring among general patient populations, and with some risk groups, such as those suffering from depression (Brown 2014). Of the estimated 1.2 million emergency department (ED) visits involving nonmedical use of pharmaceuticals in 2011, nearly 30% involved narcotic pain relievers. (Crane 2015) ED visits involving nonmedical use of narcotic pain relievers increased 117 percent from 2005 to 2011. (Crane 2015)

The Centers for Disease Control and Prevention (CDC), the American College of Emergency Physicians (ACEP), the American Academy of Emergency Medicine (AAEM), the Emergency Medicine Patient Safety Foundation (Papa 2013), Washington State (Neven 2012), the Medical Board of California (Brown 2013), the Maryland Hospital Association (MHA 2014) and the New York City Department of Health and Mental Hygiene (Chu 2013) are among the organizations that recommend opioids only if the severity of the pain is reasonably assumed to warrant their use, or if the pain is refractory to other analgesics, and even then only for short durations or in small quantities. According to the CDC, “Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids. Three days or less will often be sufficient; more than seven days will rarely be needed.” (Dowell CDC 2016)

A study of opioid use among over 1 million commercially-insured, opioid-naïve, cancer-free adults demonstrated that an increase in the probability of long-term opioid use increases most sharply in the first days of therapy, particularly after 5 days have been prescribed (Shah 2017). Few acutely painful conditions treated in the emergency department require more than a short 3-day course of opioid therapy. (Rodgers 2012) Longer courses of opioid treatment are associated with increased risk of physical dependence, abuse (Logan 2013) and disability. (Franklin 2008) In addition, opioid use beyond 3 days results in diminished efficacy and potential increased pain sensitivity (Brush 2012).

A recent report from the Office of the Inspector General (OIG) noted that 5 million Medicare Part D beneficiaries received opioids for 3 months or more in 2016, thus substantially increasing their risk of opioid dependence. Of these 5 million beneficiaries, 3.6 million received opioids for 6 or more months and nearly

610,000 received opioids for the entire year. More concerning is that nearly 90,000 Medicare Part D beneficiaries are at serious risk of opioid misuse or overdose. In total, over 115,000 clinicians ordered opioids for at least one beneficiary at serious risk of opioid misuse or overdose. (OIG 2017)

Studies have shown that there is wide variation in opioid prescribing practices, which includes numbers of pills and prescription duration in addition to choice of pain medication. In one study, prescribing rates ranged from 33 to 332 prescriptions per 1000 visits. In another study, the median days of supply for acute pain was 5 days but 10% of prescriptions were written for 30 days or more. (Smulowitz 2016, Liu 2013)

Statistics from the OIG report and studies demonstrate a significant performance gap in the duration of opioid prescriptions as they differ from that recommended by national guidelines. (OIG 2017, Smulowitz 2016, Liu 2013)

In addition, extended-release (ER) and long-acting (LA) opioids include methadone, transdermal fentanyl, and extended-release versions of opioids such as oxycodone, oxymorphone, hydrocodone, and morphine. For those patients prescribed opioids, even for short durations, the Centers for Disease Control and Prevention (CDC), the American Academy of Emergency Medicine (AAEM), the Emergency Medicine Patient Safety Foundation (Papa 2013), Washington State (Neven 2012), the Medical Board of California (Brown 2013), the Maryland Hospital Association (MHA 2014) and the New York City Department of Health and Mental Hygiene (Chu 2013) all recommend against the use of long-acting opioids. In addition, the American College of Emergency Physicians (ACEP) notes that LA/ER products such as oxycodone ER (OxyContin), methadone, fentanyl patches, or morphine extended-release (MS Contin) should not be used for acute pain (Cantrill 2012). “The administration or prescription of long-acting opioid analgesics requires the capability for long-term monitoring for both pain relief and for signs of dependence and addiction.” (Pappa EMPSF 2013) “Given longer half-lives and longer duration of effects [as well as risk for respiratory depression] with ER/LA opioids such as methadone, fentanyl patches, or extended release versions of opioids such as oxycodone, oxymorphone, or morphine, clinicians should not prescribe ER/LA opioids for the treatment of acute pain.” (Dowell CDC 2016)

Long-acting opioids are associated with higher risk for detrimental and potentially life-threatening side effects of opiate medications and do not have a role in the treatment of acute pain syndromes (Keuhn 2012, Nelson 2012). The pharmacokinetics of these medications result in an unpredictable peak effect and increase the risk of respiratory depression. Additionally, prescriptions for long-acting and extended-release opiates are more susceptible to diversion and non-medical opioid use (Nelson 2012) and raise the risk of opioid overdose death. (Garg 2017)

A recent cohort study of Veterans Affairs patients found initiation of therapy with an ER/LA opioid associated with greater risk for unintentional, nonfatal overdose than initiation with an immediate-release opioid (hazard ratio [HR], 2.33; 95% CI, 1.26-4.32), with risk greatest in the first two weeks after initiation of treatment (HR, 5.25; 1.88-14.72) (Miller 2015). In a retrospective cohort study between 1999 and 2012 of Tennessee Medicaid patients with chronic non-cancer pain and no palliative or end-of-life care, the mortality risk was four times greater for the long acting cohort during the first month of therapy. (Ray 2016).

Given the serious risks associated with ER/LA opioids, this class of medications is indicated specifically for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment in patients for whom other treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain (FDA 2013).

**2024 Measures Specifications**  
*Updated 2023.12.20*

Methadone has been associated with disproportionate numbers of overdose deaths relative to the frequency with which it is prescribed for pain. (Paulozzi 2012).

In a large, commercially-insured adult population, greater than 3 million eligible enrollees who received at least one opioid prescription were analyzed for indicators of potential opioid misuse (Liu 2013). Among those prescribed LA/ER opioids, a quarter of patients were treated for acute pain, despite guideline recommendations highlighting the risks of initiating patients on LA/ER therapy, and nearly a quarter of prescriptions overlapped with other existing LA/ER opioid prescriptions, which is a recognized indicator for opioid misuse (Liu 2013) and nearly doubles the risk of overdose and mortality. (Miller 2015, Ray 2016)

### Selected References:

- Brown EG. Guidelines for Prescribing Controlled Substances for Pain. Dec. 2014. [http://www.mbc.ca.gov/licensees/prescribing/pain\\_guidelines.pdf](http://www.mbc.ca.gov/licensees/prescribing/pain_guidelines.pdf)
- Brush DE. Complications of long-term opioid therapy for management of chronic pain: the paradox of opioid-induced hyperalgesia. J Med Toxicol;Dec 2012;8:387-92.
- Cantrill SV, Brown MD, Carlisle RJ, et al.; American College of Emergency Physicians (ACEP) Opioid Guideline Writing Panel. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med 2012;60:499–525.
- Centers for Medicare and Medicaid Services (CMS). Announcement of Calendar Year (CY) 2018 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter and Request for Information. April 3, 2017. <https://www.cms.gov/Medicare/Health-Plans/MedicareAdvgtgSpecRateStats/Downloads/Announcement2018.pdf>
- Chu J, Farmer B, Ginsburg B, Hernandez S, Kenny J, Majlesi N. New York City emergency department discharge opioid prescribing guidelines. New York, NY: New York City Department of Health and Mental Hygiene; 2013. [http://www.orangecountygov.com/filestorage/124/1348/16688/NYC\\_ER\\_opioid-prescribing-guidelines.pdf](http://www.orangecountygov.com/filestorage/124/1348/16688/NYC_ER_opioid-prescribing-guidelines.pdf)
- Cheng D, Majlesi N. Clinical practice statement: emergency department opioid prescribing guidelines for the treatment of non-cancer related pain. Milwaukee, WI: American Academy of Emergency Medicine; 2013.
- Crane, E. H. (2015). The CBHSQ Report: Emergency Department Visits Involving Narcotic Pain Relievers. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. [https://www.samhsa.gov/data/sites/default/files/report\\_2083/ShortReport-2083.html](https://www.samhsa.gov/data/sites/default/files/report_2083/ShortReport-2083.html)
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep 2022;71(No. RR-3):1–95. <https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm>
- FDA Approved Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting (ER/LA) Opioid Analgesics <https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=RemsDetails.page&REMS=17>
- Franklin GM, Stover BD, Turner JA, Fulton-Kehoe D, Wickizer TM. Early opioid prescription and subsequent disability among workers with back injuries: the Disability Risk Identification Study Cohort. Spine (Phila Pa 1976) 2008;33:199-204.
- Garg RK, Fulton-Kehoe D, Franklin GM. Patterns of Opioid Use and Risk of Opioid Overdose Death Among Medicaid Patients. Med Care. 2017 Jul;55(7):661-668. <https://www.ncbi.nlm.nih.gov/pubmed/28614178>



- Hartung DM, Middleton L, Haxby DG, Koder M, Ketchum KL, Chou R. Rates of adverse events of long-acting opioids in a state Medicaid program. *Ann Pharmacother* 2007;41:921–8. <http://dx.doi.org/10.1345/aph.1K066>
- Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain. A randomized prospective study. *Spine (Phila Pa 1976)* 1998;23:2591–600. <http://dx.doi.org/10.1097/00007632-199812010-00014>
- Kuehn BM. Methadone overdose deaths rise with increased prescribing for pain. *JAMA*;2012; 308:749-50.
- Liu Y, Logan JE, Paulozzi LJ, Zhang K, Jones CM. Potential misuse and inappropriate prescription practices involving opioid analgesics. *Am J Manag Care*. 2013 Aug;19(8):648-65.
- Logan J, Liu Y, Paulozzi L, Zhang K, Jones C. Opioid Prescribing in Emergency Departments: The Prevalence of Potentially Inappropriate Prescribing and Misuse. *Med Care*. Apr 2013.
- Maryland Hospital Association (MHA). Maryland emergency department opioid prescribing guidelines. 2014 <http://www.mhaonline.org/docs/default-source/Resources/Opioid-Resources-for-Hospitals/maryland-emergency-department-opioid-prescribing-guidelines.pdf>
- Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. *JAMA Intern Med* 2015;175:608–15. [http:// dx.doi.org/10.1001/jamainternmed.2014.8071](http://dx.doi.org/10.1001/jamainternmed.2014.8071)
- Nelson LS, Perrone J. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS). *JAMA*;2012; 308:457-8.
- Neven DE, Sabel JC, Howell DN, Carlisle RJ. The development of the Washington State emergency department opioid prescribing guidelines. *J Med Toxicol*. 2012 Dec;8(4):353-9. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3550252/>
- Office of the Inspector General (OIG). Opioids in Medicare Part D: Concerns about Extreme Use and Questionable Prescribing. HHS OIG Data Brief: OEI-02-17-00250. 2017 <https://oig.hhs.gov/oei/reports/oei-02-17-00250.pdf>
- Pappa A. Emergency Medicine Patient Safety Foundation (EMPSF) Prescribing and dispensing opioids in the emergency department. January 2013. <http://www.premiersafetyinstitute.org/wp-content/uploads/Prescribing-Dispensing-Opioids-ER-Hallam-Final.pdf>
- Paulozzi L, Mack KA, Jones CM. Vital signs: Risk for overdose from methadone used for pain relief—United States, 1999–2010. *MMWR Morb Mortal Wkly Rep* 2012;61:493–7.
- Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain. *JAMA*. 2016 Jun 14;315(22):2415-23.
- Rodgers J, Cunningham K, Fitzgerald K, Finnerty E. Opioid consumption following outpatient upper extremity surgery. *J Hand Surg Am*; Apr 2012;37:645-50.
- Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? *J Pain Symptom Manage* 1999;18:271–9. [http:// dx.doi.org/10.1016/S0885-3924\(99\)00079-2](http://dx.doi.org/10.1016/S0885-3924(99)00079-2)
- Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015. *MMWR Morb Mortal Wkly Rep* 2017;66:265–269. DOI: <http://dx.doi.org/10.15585/mmwr.mm6610a1>
- Smulowitz PB, Cary C, Boyle KL, Novack V, Jagminas L. Variation in opioid prescribing patterns between ED providers. *Intern Emerg Med*. 2016 Dec;11(8):1121-1124. Epub 2016 Jul 16.

<https://www.ncbi.nlm.nih.gov/pubmed/27424280>

- Volkow ND, McLellan TA, Cotto JH. Characteristics of opioid prescriptions in 2009. JAMA. 2011;305:1299-1301
- Von Korff M, Merrill JO, Rutter CM, Sullivan M, Campbell CI, Weisner C. Time-scheduled vs. pain-contingent opioid dosing in chronic opioid therapy. Pain 2011;152:1256–62. <http://dx.doi.org/10.1016/j.pain.2011.01.005>

## **E-CPR (Emergency – Clinical Performance Registry) Measure #56**

**Measure Title:** Opioid Withdrawal: Initiation of Medication-Assisted Treatment (MAT) and Referral to Outpatient Opioid Treatment

**Inverse Measure:** No

**Measure Description:** Percentage of Patients Presenting with Opioid Withdrawal Who Were Given Medication-Assisted Treatment and Referred to Outpatient Opioid Treatment

**National Quality Strategy Domain:** Patient Safety

**Care Setting:** Ambulatory Care: Urgent Care; Ambulatory; Ambulatory Care: Hospital; Ambulatory Care: Clinician Office/Clinic; Outpatient Services; Emergency Department and Services; Hospital Inpatient; Hospital; Hospital Outpatient

**Published Specialty:** Emergency Medicine; Family Medicine; Hospitalist; Internal Medicine; Primary Care; Urgent Care

**Telehealth:** Yes

**Type of Measure:** Process, High Priority

**High Priority Type:** Opioid-Related

**Meaningful Measure Area:** Prevention and Treatment of Opioid and Substance Use Disorders

**Current Clinical Guideline:** U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (HHS SAMHSA)

**Published Clinical Category:** Opioid Management

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Patients Who Were Given Medication-Assisted Treatment (MAT) and, at Time of Discharge to Home or Home Health, Referred to Outpatient Opioid Treatment

- **Performance Met (VE281):** Buprenorphine or Methadone ordered AND, at time of discharge to home or home health, outpatient opioid treatment referral made.
- **Medical Performance Exclusion (Denominator Exception) (VE282):** Refusal of care, allergy to medicine, altered mental status, Buprenorphine or Methadone not clinically indicated.

- **Performance Not Met (VE283):** Buprenorphine or Methadone not ordered OR Buprenorphine or Methadone ordered BUT outpatient opioid treatment referral not made at time of discharge to home or home health.
- Note: Combination therapies ordered that include Buprenorphine or Methadone (such as Suboxone) are also acceptable.
- Note: For patients who are not discharged in an encounter, an order of Buprenorphine or Methadone is sufficient to meet the Numerator criteria.

**Numerator Exclusions:** None

**Denominator:**

- Any patient  $\geq$  18 years of age evaluated by the Eligible Professional in the Emergency Department, Urgent Care, Clinic, Inpatient, or Observation Status settings (E/M Codes 99234-99236, 99238-99239, 99281-99285, 99291-99292, 99202-99205, 99212-99215 AND Place of Service Indicator: 02, 11, 19, 20, 21, 22, 23 OR equivalent in standardized code sets) PLUS
- Diagnosis of opioid abuse or dependence with withdrawal
  - ICD-10: F11.13, F11.23
- Transferred to another acute care facility (same or higher level of care), eloped, AMA or expired patients are excluded (**V0704**)

**Denominator Exclusions:** None

**Rationale:**

According to the 2019 National Survey on Drug Use and Health, 2 million people in the United States had an opioid use disorder in 2018. In 2018, 47,600 people died from overdosing on opioids – that means that more than 130 deaths occurred every day from opioid-related drug overdoses.

Patients with opioid use disorder represent a vulnerable population that often seeks care in Emergency Departments and acute care hospitals. Often, they seek care due to withdrawal symptoms which may include abdominal cramping, nausea, vomiting, diarrhea, anxiety, restlessness, tremor, and muscle aches. Without appropriate treatment, these individuals may seek continued use of prescription opioids and/or illegal opioids such as heroin to transiently alleviate their symptoms. Medication Assisted Treatment (MAT) with opioid agonist treatment including Buprenorphine and Methadone has been shown to be effective in treating these individuals. These medications decrease withdrawal, craving, and opioid use.

A randomized clinical trial performed involving 329 opioid-dependent patients from 2009-2013 demonstrated superiority of buprenorphine treatment compared to brief intervention and referral. Treatment led to increased engagement in addiction treatment, reduced self-reported illicit opioid use, and decreased use of inpatient addiction treatment services.

**Selected References:**

1. D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. *JAMA*. 2015 Apr 28;313(16):1636-44. doi: 10.1001/jama.2015.3474. PMID: 25919527; PMCID: PMC4527523.
2. D'Onofrio G, Chawarski MC, O'Connor PG, Pantalon MV, Busch SH, Owens PH, Hawk K, Bernstein SL, Fiellin DA. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention. *J Gen Intern Med*. 2017 Jun;32(6):660-666. doi: 10.1007/s11606-017-3993-2. Epub 2017 Feb 13. PMID: 28194688; PMCID: PMC5442013.
3. Samuels EA, D'Onofrio G, Huntley K, Levin S, Schuur JD, Bart G, Hawk K, Tai B, Campbell CI, Venkatesh AK. A Quality Framework for Emergency Department Treatment of Opioid Use Disorder. *Ann Emerg Med*. 2019 Mar;73(3):237-247. doi: 10.1016/j.annemergmed.2018.08.439. Epub 2018 Oct 11. PMID: 30318376; PMCID: PMC6817947.
4. D'Onofrio G, McCormack RP, Hawk K. Emergency Departments – A 24/7/365 Option for Combating the Opioid Crisis. *N Engl J Med*. 2018 Dec;379:2487-2490.  
[https://www.nejm.org/doi/full/10.1056/NEJMp1811988?url\\_ver=Z39.88-2003&rfr\\_id=ori%3Arid%3Acrossref.org&rfr\\_dat=cr\\_pub%3Dpubmed](https://www.nejm.org/doi/full/10.1056/NEJMp1811988?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed)
5. U.S. Department of Health and Human Services. Opioid Facts and Statistics. 2019.  
[https://www.hhs.gov/opioids/sites/default/files/2019-11/Opioids%20Infographic\\_letterSizePDF\\_10-02-19.pdf](https://www.hhs.gov/opioids/sites/default/files/2019-11/Opioids%20Infographic_letterSizePDF_10-02-19.pdf)
6. Substance Abuse and Mental Health Services Administration (SAMHSA). Medications, Counseling, and Related Conditions. 20220. <https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions#opioid-dependency-medications>

## **E-CPR (Emergency – Clinical Performance Registry) Measure #58**

**Measure Title:** Patient-Reported Understanding of Discharge Diagnosis and Plan of Care

**Inverse Measure:** No

**Measure Description:** Percentage of Adult Patients Who Completed a Survey Regarding Their Care Visit Who Reported Understanding of Their Discharge Diagnosis and Plan of Care

**National Quality Strategy Domain:** Person and Caregiver-Centered Experience and Outcomes

**Care Setting:** Emergency Department and Services; Ambulatory Care: Urgent Care; Ambulatory; Ambulatory Care: Hospital; Ambulatory Care: Clinician Office/Clinic; Outpatient Services; Hospital; Hospital Outpatient

**Published Specialty:** Emergency Medicine; Acute Care; Hospitalist; Internal Medicine; Family Medicine

**Telehealth:** Yes

**Type of Measure:** Patient-Reported Outcome-Based Performance Measure; High Priority

**High Priority Type:** Patient Experience

**Meaningful Measures Area:** Patient’s Experience of Care

**Published Clinical Category:** Patient-Reported Outcome

**Reporting Measure:** Percentage of adult patients who completed a survey regarding their care visit who reported understanding of their discharge diagnosis and plan of care.

**Number of Performance Rates:** 1

**Measures Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Patients Who Reported Understanding of Their Discharge Diagnosis and Plan of Care from their care visit

**Definitions:** Understanding of the discharge diagnosis and plan of care is defined as a response of (A) “Yes, strongly agree” or (B) “Yes, mostly” on the following survey prompt:

“I understood my diagnosis and plan of care” with response options of (D) “No,” (C) “Yes, somewhat,” (B) “Yes, mostly,” and (A) “Yes, strongly agree”

**Numerator Options:**

- **Performance Met: (VE286)** Patient reported understanding of their discharge diagnosis and plan of care (i.e., A or B on the survey response)
- **Performance Not Met: (VE287)** Patient did NOT report understanding of their discharge diagnosis and plan of care (i.e., C or D on the survey response)

**Numerator Exclusions:** None

**Denominator:**

- Any patient  $\geq 18$  years of age evaluated by the Eligible Professional in the Emergency Department or Urgent Care Clinic PLUS
- Completed a survey regarding their care visit after discharge **(VE285)**.
- Disposition of Discharged
- Transferred, eloped, AMA, or expired patients are excluded **(V0704)**

**Denominator Exclusions:** None

**Rationale:**

Patient-reported outcomes are a high priority for CMS and other organizations. The purpose of these measures is to obtain the perspectives of patients and to engage patients and their families in their care. Patient-reported outcomes are particularly limited in Emergency Medicine.

Communication between the clinician and the patient is a key component of high quality care delivery. However, due to the complicated and sometimes chaotic environment in acute care settings, communication with patients can be challenging. Communication with patients is particularly important during transitions of care such as the time of discharge. Without adequate communication, particularly regarding the discharge diagnosis, there can be downstream repercussions such as ED bounce backs/readmissions, lack of adherence to treatment or recommendations, or delays in appropriate follow-up.

The purpose of this patient-reported outcome measure is to promote communication between the clinician and the patient to ensure adequate understanding of the discharge diagnosis.

## **E-CPR (Emergency – Clinical Performance Registry) Measure #59**

**Measure Title:** Patient Reported Trust in Provider

**Inverse Measure:** No

**Measure Description:** Percentage of Adult Patients Who Completed a Survey Regarding Their Care Visit Who Reported they Would Trust the Doctor/Provider to Care for their Friends/Family

**National Quality Strategy Domain:** Person and Caregiver-Centered Experience and Outcomes

**Care Setting:** Ambulatory; Ambulatory Care: Clinician office/Clinic; Ambulatory Care: Hospital; Ambulatory Care: Urgent Care; Emergency Department and Services; Hospital; Hospital Inpatient; Hospital Outpatient; Outpatient Services

**Published Specialty:** Emergency Medicine; Acute Care; Hospitalist; Internal Medicine; Urgent Care; Primary Care; Family Medicine

**Telehealth:** Yes

**Type of Measure:** Patient Experience of Care; High Priority

**High Priority Type:** Patient Experience

**Published Clinical Category:** Patient Experience

**Reporting Measure:** Percentage of adult patients who completed a survey regarding their care visit who reported they would trust the doctor/provider to care for their friends/family.

**Number of Performance Rates:** 1

**Measures Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Patients Who Reported they would trust the Doctor/Provider to care for their friends/family

**Definitions:** Trust the Doctor/Provider to care for their friends/family is defined as a response of (A) “Yes, strongly agree” or (B) “Yes, mostly” on the following survey prompt: “I would trust the doctor/provider to care for my friends/family.” with response options of (D) “No,” (C) “Yes, somewhat,” (B) “Yes, mostly,” and (A) “Yes, strongly agree”



#### Numerator Options:

- **Performance Met (VE288):** Patient reported they would trust the doctor/provider to care for their friends/family (i.e., A or B on the survey response)
- **Performance Not Met (VE289):** Patient did NOT report they would trust the doctor/provider to care for their friends/family (i.e., C or D on the survey response)

**Numerator Exclusions:** None

#### **Denominator:**

- Any patient ≥18 years of age evaluated by the Eligible Professional in Emergency Department, Urgent Care Center, or Inpatient setting PLUS
- Completed a survey regarding their care visit (**VE290**).

**Denominator Exclusions:** None

#### **Rationale:**

Patient experience, in this case trust in their provider, is a high priority for CMS and other organizations. The literature identifies the “attitude” of patient empowerment leads to “behaviors” of patient involvement, patient engagement, and patient participation (Hickmann, Richter, & Schlieter, 2022). Patient engagement thus improves quality of care, the likelihood of achieving treatment results and patient satisfaction (Marzban, Najafi, Agolli, & Ashrafi, 2022). CAHPS is a robust measure including multiple questions targeted to patient experience but does not incorporate trust in the provider. While there are existing patient & physician trust measurement tools, all are robust with 10-51 questions. This measure aims to simplify into a reliable, feasible, valid measurement based on a singular question to quantify trust extending to loved ones. A meta-analysis to identify association between trust and health outcome in various care settings and diagnoses found a “small to moderate correlation between trust and health outcome ( $r = 0.24$ , 95% CI: 0.19 to 0.29) based on 47 studies” (Birkhäuser J, 2017) of various trust surveys, demonstrating the measurement of trust has health outcomes.

The purpose of this measure is to obtain direct feedback from patients regarding trust in their providers, by proxy of trust to their loved ones, as a measure of patient engagement.

#### **Selected References:**

1. Hickmann, E., Richter, P., & Schlieter, H. (2022). All together now - patient engagement, patient empowerment, and associated terms in personal healthcare. *BMC Health Services Research*, 22:1116.
2. Marzban, S., Najafi, M., Agolli, A., & Ashrafi, E. (2022). Impact of Patient Engagement on Healthcare Quality: A Scoping Review. *Journal of Patient Experience*, 1-12.
3. Birkhäuser J, G. J. (2017). Trust in the health care professional and health outcome: A meta-analysis. *PLoS One*, 12(2).

## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #20**

**Measure Title:** Clostridium Difficile – Risk Assessment and Plan of Care

**Inverse Measure:** No

**Measure Description:** Percentage of Adult Patients Who Had a Risk Assessment for C. difficile Infection and, If High-Risk, Had a Plan of Care for C. difficile Completed on the Day Of or Day After Hospital Admission

**National Quality Strategy Domain:** Patient Safety

**Care Setting:** Hospital: Inpatient; Hospital

**Published Specialty:** Critical Care; Hospitalist;

**Telehealth:** Yes

**Type of Measure:** Process, High Priority

**High Priority Type:** Patient Safety

**Meaningful Measure Area:** Healthcare-associated Infections

**Current Clinical Guideline:** This preventive screening is supported by the CDC, IDSA, SHEA, AHA, and Joint Commission.

**Published Clinical Category:** C. Diff

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Patients that had a risk assessment for C. difficile infection and, if high-risk, a plan of care documented on the day of or day after hospital admission

### Definitions:

- Risk assessment (e.g., IDSA score, SHEA score, ZAR criteria):
  - Previous C. difficile infection
  - Recent antibiotic use (60-90 days prior to current admission)
  - Recent contact with healthcare facility (60-90 days prior to current admission)
  - Age ≥ 65
  - Recent use of proton pump inhibitor (PPI) or histamine receptor 2 antagonists (H2RA)
  - Diagnosis and procedure history (e.g., IBD, immunosuppression or hemodialysis)

- Plan of Care
  - Contact precautions if diarrhea is present.
  - Stool assay
  - Initiation of antibiotics if indicated.

Numerator Options:

- Performance Met (**VH260**): Patients who did have a C. difficile infection risk assessment, AND if high-risk, a plan of care for C. difficile documented on the day of or day after hospital admission.
- Medical Performance Exclusion (Denominator Exception) (**VH261**): Patients who did not have a C. difficile infection risk assessment, AND if high risk, a plan of care for C. difficile for medical reasons documented by the Eligible Professional (e.g., C. difficile infection already documented prior to hospital admission, patients unable to provide history, patients on comfort measures)
- Performance Not Met (**VH262**): Patients who did not have a C. difficile infection risk assessment, AND if high risk, a plan of care for C. difficile documented on the day of or day after hospital admission, no reason specified

**Denominator:**

- Any patient ≥ 18 years of age evaluated by the Eligible Professional Admitted in the inpatient acute care setting, including intensive care unit (E/M Codes 99221- 99223 99234-99236 & 99291-99292 AND Place of Service Indicator: 02 or 21 OR equivalent in standardized code sets)
- Transferred, eloped or AMA patients are excluded (**V0700**)

**Denominator Exclusions:** None

**Rationale:**

*Clostridium difficile* is recognized as one of the most challenging pathogens in hospital and community healthcare settings, with a steadily rising global incidence of infection and concordant increase in mortality. (Tavetin 2013, LoVechio 2012) The Centers for Disease Control and Prevention (CDC) has assigned C. *difficile* infections (CDI) as an urgent threat because of its association with antibiotic use and high mortality and morbidity. (CDC 2013) Approximately 83,000 of the half a million patients who developed C. *difficile* in 2011 experienced at least one recurrence, and 29,000 died within 30 days of the initial diagnosis (CDC 2013). Hospitalized CDI patients have a 2.5 times increased 30-day mortality rate compared to in-patients without diarrhea; the CDI-related mortality is approximately 10%. (CDC 2013)

C. *difficile* infections can be prevented by using infection control recommendations and more careful antibiotic use. Numerous guidelines from the Centers for Disease Control and Prevention (CDC), the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the American Hospital Association (AHA), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Joint Commission recommend risk assessment of hospitalized patients to guide prevention and treatment. (Dubberke 2014, Cohen 2010, Bauer 2009). Multiple risk assessment tools have been developed (Cohen 2010, Tabak 2015, Kuntz 2016, Smith 2014) and different hospitals implement these assessments according to local protocols. Key risk factors identified in these assessment tools include previous CDI, recent contact with a healthcare facility, recent antibiotic use, immune status, and stomach acid reducing medications.

In the United States, the proportion of hospital discharges in which a patient received a discharge diagnosis for

CDI more than doubled between 2000 and 2009. (Lucado 2012) Approximately 96% of patients with symptomatic *C. difficile* infection had received antimicrobials within the 14 days before the onset of diarrhea and that all had received an antimicrobial within the previous 3 months. (Olson 1994) There is an increased risk of CDI that can persist for many weeks after cessation of antimicrobial therapy and which results from prolonged perturbation of the normal intestinal flora. (Anand 1994) Evidence also suggests that CDI resulting from exposure to *C. difficile* in a healthcare facility can have onset after discharge. (Palmore 2005, Chang 2006, Mayfield 2006). Advanced age is also an important risk factor for CDI, as evidenced by the several fold higher age-adjusted rate of CDI among persons more than 64 years of age. (McDonald 2006, Pepin 2004). Immunosuppression (chemotherapy, HIV, etc) is another risk factor for CDI. (Bilgrami 1999, Gorshulter 2001, Sanchez 2005) Epidemiologic associations with CDI have also been found for acid-suppressing medications such as histamine-2 blockers (HR2A) and proton pump inhibitors (PPI). (Dial 2005, Cunningham 2003, Dial 2004).

The CDC, IDSA, and SHEA currently recommend placing patients with diarrhea under contact precautions while *C. difficile* testing is pending. To decrease transmission, it is essential to place symptomatic patients under contact precautions as soon as diarrhea symptoms are recognized, as this is the period of greatest *C. difficile* shedding and

Contamination (Sethi 2010, Dubberke 2014) Contact precautions should remain in place for the duration of CDI illness when caring for patients with CDI, and some experts recommend continuing contact precautions for at least 48 hours after diarrhea resolves. (Sethi 2010). Assuring that patients with CDI are receiving appropriate severity-based treatment for their infection should be an additional goal for antimicrobial stewardship programs and may improve clinical outcome of CDI in these patients. (Dubberke 2014).

Despite recent CDI infection and control efforts, CDI remains at historically high rates. (Dubberke 2014) The CDC's 2021 Annual Report for the Emerging Infections Program for *Clostridium difficile* Infection reported the incidence of healthcare associated CDI to be 54.3 per 100,000, community acquired to be 55.9 per 100,000, and the overall incidence rate to be 110.2 per 100,000. (CDC 2023) Multiple states have reported increased rates of *C. difficile* infection and mortality, noting more severe disease that is more virulent, and more resistant to traditional antibiotics for treatment. (CDC 2017 Fact Sheet)

#### **Selected References:**

- Anand A, Bashey B, Mir T, et al. Epidemiology, clinical manifestations, and outcome of *Clostridium difficile*-associated diarrhea. *Am J Gastroenterol* 1994;89:519–523.
- Bauer MP, Kuijper EJ, van Dissel JT; European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for *Clostridium difficile* infection (CDI). *Clin Microbiol Infect*. 2009 Dec;15(12):1067-79.
- Bilgrami S, Feingold JM, Dorsky D, et al. Incidence and outcome of *Clostridium difficile* infection following autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* 1999;23:1039–1042.
- Centers for Disease Control and Prevention. 2023. Emerging Infections Program, Healthcare-Associated Infections – Community Interface Surveillance Report, *Clostridioides difficile* infection (CDI), 2021. Available at: <https://www.cdc.gov/hai/eip/Annual-CDI-Report-2021.html>
- Centers for Disease Control and Prevention. *Clostridium difficile* Infections Across the U.S. Fact Sheet. Last accessed Oct 2017. <https://www.cdc.gov/hai/eip/pdf/cdiff-factsheet.pdf>
- Centers for Disease Control & Prevention. Antibiotic Resistance Threats in the United States, 2013. U.S. Department of Health and Human Services.2013. <http://www.cdc.gov/drugresistance/threat-report->

[2013/pdf/ar-threats-2013-508.pdf](http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_faqs_HCP.html)

- Centers for Disease Control and Prevention. Frequently asked questions about *Clostridium difficile* for healthcare providers. Centers for Disease Control and Prevention website. 2005. [http://www.cdc.gov/HAI/organisms/cdiff/Cdiff\\_faqs\\_HCP.html](http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_faqs_HCP.html).
- Chang H, Parada J, Evans C, et al. Onset of symptoms and time to diagnosis of *Clostridium difficile* diarrhea among outpatients discharged from an acute care hospital [abstract]. In: Proceedings of The 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; March 18–21, 2006; Chicago, IL: 108–109.
- Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol*. 2010 May;31(5):431-55. doi: 10.1086/651706.
- Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for *clostridium difficile* diarrhoea. *J Hosp Infect* 2003;54:243–245.
- Dial S, Alrasadi K, Manoukian C, et al. Risk of *Clostridium difficile* diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. *CMAJ* 2004;171:33–38.
- Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*–associated disease. *JAMA* 2005;294:2989–2995.
- Dubberke ER, Carling P, Carrico R, Donskey CJ, Loo VG, McDonald LC, Maragakis LL, Sandora TJ, Weber DJ, Yokoe DS, Gerding DN. Strategies to prevent *Clostridium difficile* infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol*. 2014 Sep;35 Suppl 2:S48-65
- Gorschluter M, Glasmacher A, Hahn C, et al. *Clostridium difficile* infection in patients with neutropenia. *Clin Infect Dis* 2001;33:786–791.
- Kuntz JL, Smith DH, Petrik AF, Yang X, Thorp ML, Barton T, Barton K, Labreche M, Spindel SJ, Johnson ES. Predicting the Risk of *Clostridium difficile* Infection upon Admission: A Score to Identify Patients for Antimicrobial Stewardship Efforts. *Perm J*. 2016 Winter;20(1):20-5.
- Lo Vecchio A, Zacur GM. *Clostridium difficile* infection: an update on epidemiology, risk factors, and therapeutic options. *Curr Opin Gastroenterol*. 2012;28:1–9.
- Lucado J, Gould C, Elixhauser A. *Clostridium difficile* Infection (CDI) Hospital Stays, 2009. HCUP Statistical Brief 124. Rockville, MD: Agency for Healthcare Research and Quality, 2012. <http://www.hcup-us.ahrq.gov/reports/statbriefs/sbl24.pdf>
- Mayfield J, McMullen K, Dubberke E. Comparison of *Clostridium dif-ficile*–associated disease rates using a traditional vs. expanded definition. In: Proceedings of The 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; March 18–21, 2006; Chicago, IL: 115.
- McDonald LC, Owings M, Jernigan DB. *Clostridium difficile* infection in patients discharged from US short-stay hospitals, 1996–2003. *Emerg Infect Dis* 2006;12:409–415.
- Olson MM, Shanholtzer CJ, Lee JT Jr, et al. Ten years of prospective *Clostridium difficile*–associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. *Infect Control Hosp Epidemiol* 1994;15:371–381.
- Palmore TN, Sohn S, Malak SF, et al. Risk factors for acquisition of *Clostridium difficile*–associated diarrhea among outpatients at a cancer hospital. *Infect Control Hosp Epidemiol* 2005;26:680–684.
- Pepin J, Valiquette L, Alary ME, et al. *Clostridium difficile*–associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. *CMAJ* 2004;171:466-472.
- Samore MH, DeGirolami PC, Tlucko A, et al. *Clostridium difficile* colonization and diarrhea at a tertiary care

**2024 Measures Specifications**

Updated 2023.12.20

hospital. Clin Infect Dis 1994;18: 181–187.

- Sanchez TH, Brooks JT, Sullivan PS, et al. Bacterial diarrhea in persons with HIV infection, United States, 1992–2002. Clin Infect Dis 2005;41:1621–1627.
- Sethi AK, Al Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol 2010;31(1):21-27.
- Smith LA, Chan CK, Halm M, Slattery W, Lindquist R, Savik K. Development and validation of a Clostridium difficile risk assessment tool. AACN Adv Crit Care. 2014 Oct-Dec;25(4):334-46.
- Tabak YP, Johannes RS, Sun X, Nunez CM, McDonald LC. Predicting the risk for hospital-onset Clostridium difficile infection (HO-CDI) at the time of inpatient admission: HO-CDI risk score. Infect Control Hosp Epidemiol. 2015 Jun;36(6):695-701. Epub 2015 Mar 10.
- Tattevin P, Buffet-Bataillon S, Donnio PY, Revest M, Michelet C. Clostridium difficile infections: do we know the real dimensions of the problem? Int J Antimicrob Agents. 2013;42:S36–40.

## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #23**

**Measure Title:** Avoidance of Echocardiogram and Carotid Ultrasound for Syncope

**Inverse Measure:** No

**Measure Description:** Percentage of Patients Presenting with Syncope Who Did Not Have an Echocardiogram or Carotid Ultrasound Ordered

**National Quality Strategy Domain:** Efficiency and Cost Reduction

**Care Setting:** Hospital: Inpatient; Hospital

**Published Specialty:** Hospitalist; Internal Medicine

**Telehealth:** Yes

**Type of Measure:** Process, High Priority

**High Priority Type:** Appropriate Use

**Meaningful Measure Area:** Appropriate Use of Healthcare

**Current Clinical Guideline:** American College of Cardiology, American Heart Association, European Society of Cardiology

**Published Clinical Category:** Syncope

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Patients That Did NOT Have an Echocardiogram or Carotid Ultrasound Ordered

- Performance Met (**VH268**): Echocardiogram AND Carotid Ultrasound NOT ordered.
- Medical Performance Exclusion (Denominator Exception) (**VH269**): Echocardiogram or Carotid Ultrasound ordered with documentation of 1) cardiac etiology of syncope suspected or determined (i.e., abnormal cardiac exam (new murmur, bruit), abnormal EKG, cardiac dysrhythmia, abnormal cardiac biomarkers, chest pain, shortness of breath, known heart disease, known or suspected structural heart disease) OR 2) neurologic etiology of syncope suspected or determined (i.e., abnormal neurologic exam, focal neurologic deficit)
- Performance Not Met (**VH270**): Echocardiogram and/or Carotid Ultrasound ordered.

**Numerator Exclusions:** None

**Denominator:**

- Any patient ≥ 18 years of age evaluated by the Eligible Professional Admitted in the inpatient acute care setting (E/M Codes 99221- 99223, 99231-99233, 99234-99236 & 99291-99292 AND Place of Service Indicator: 02 or 21 OR equivalent in standardized code sets) PLUS
- Admitted or Placed in Observation Status **(V0717)** PLUS
- Diagnosis of Syncope
  - ICD-10: R55
- Transferred, eloped, AMA or expired patients are excluded **(V0704)**

**Denominator Exclusions:** None

**Rationale:**

Syncope, defined as a transient loss of consciousness with rapid spontaneous recovery, is a common condition for which patients seek medical attention. It accounts for up to 6% of all hospital admissions. Given the broad range of causes (neurologic, vascular, metabolic, cardiac, psychologic, etc.) for syncope, clinicians may pursue many different diagnostic tests as part of their evaluation. Several studies have shown that many of these tests, including routine use of echocardiography and carotid ultrasonography, can be unnecessary and unlikely to contribute to the etiologic diagnosis and management of syncope. In a study of 2106 patients who received a battery of diagnostic testing during admission following a syncope episode, only 2% of echocardiograms performed revealed findings that contributed to the syncopal episode. An even smaller percentage of performed carotid ultrasounds affected the diagnosis or helped to determine the etiology of syncope. (Mendu) Another retrospective review of 128 patients admitted for syncope found that “for patients without suspected cardiac disease after history, physical examination, and electrocardiography, the echocardiogram did not appear to provide additional useful information.” (Recchia) Another study of 1038 patient records coded as “syncope” revealed that only 0.94% of performed echocardiograms and 0% of performed carotid ultrasounds helped to establish the cause of syncope. (Johnson)

Per the 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients with Syncope, “routine cardiac imaging [transthoracic echocardiography] is not useful in the evaluation of patients with syncope unless cardiac etiology is suspected on the basis of an initial evaluation, including history, physical examination, or ECG.” Also, carotid artery imaging is not recommended in the routine evaluation of patients with syncope in the absence of focal neurological findings that support further evaluation. “The evidence suggests that routine neurologic testing [including carotid ultrasound] is of very limited value in the context of syncope evaluation and management; the diagnostic yield is low, with very high cost per diagnosis.” (Shen)

According to the 2018 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Management of Syncope, echocardiogram is only indicated if there is previous known heart disease or data suggestive of structural heart disease or syncope secondary to cardiovascular cause. (Brignole)

**Selected References:**

1. Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the Diagnosis and Management of Syncope. European Heart Journal. 39(21) 01 Jun 2018; 1883-1948.



2. Johnson PC, Ammar H, Zohdy W, et al. Yield of diagnostic tests in evaluating syncope presenting to a community hospital. *South Med J.* 2014; 107: 707-14.
3. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients with Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Hearth Rhythm Society. *Circulation.* 2017; 136: e60-e122.
4. Mendu ML, McAvay G, Lampert R, et al. Yield of diagnostic tests in evaluating syncopal episodes in older patients. *Arch Intern Med.* 2009;169:1299–305.
5. Recchia D, Barzilai B. Echocardiography in the evaluation of patients with syncope. *J Gen Intern Med.* 1995;10:649–55

## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #24**

**Measure Title:** Appropriate Utilization of Vancomycin for Cellulitis

**Inverse Measure:** No

**Measure Description:** Percentage of Patients with Cellulitis Who Did Not Receive Vancomycin Unless MRSA Infection or Risk for MRSA Infection Was Identified

**National Quality Strategy Domain:** Efficiency and Cost Reduction

**Care Setting:** Emergency Department and Services, Hospital; Hospital Inpatient

**Published Specialty:** Acute Care; Critical Care; Emergency Medicine; Hospitalist

**Telehealth:** Yes

**Type of Measure:** Process, High Priority

**High Priority Type:** Appropriate Use

**Meaningful Measure Area:** Appropriate Use of Healthcare

**Current Clinical Guideline:** IDSA Guidelines

**Published Clinical Category:** Cellulitis

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS, MIPS Value Pathway (MVP)

**Numerator:** Patients Who Did NOT have Vancomycin (IV) Ordered Unless Known MRSA Infection Was Identified or Specific Risk for MRSA Infection Was Indicated

- Performance Met (**VH271**):
  - Vancomycin NOT ordered OR Vancomycin discontinued at admission  
OR
  - Vancomycin ordered AND MRSA infection identified or risk for MRSA infection documented (i.e., nasal colonization, prior MRSA infection, recent hospitalization, recent antibiotics, penetrating injury, IVDU, purulent cellulitis, SIRS criteria, sepsis, impaired host defense)
- Performance Not Met (**VH272**): Vancomycin ordered AND no MRSA infection identified OR no risk for MRSA infection documented

**Numerator Exclusions:** None

**Denominator:**

- Any patient greater than or equal to 18 years of age evaluated by the Eligible Professional PLUS
- Admitted or Placed in Observation Status (**V0717**) PLUS (E/M Codes 99221-23, 99234-36, 99281-85, 99291-92 AND Place of Service indicators 02, 19, 21, 22, or 23 OR equivalent in standardized code sets) PLUS
- Diagnosis of Cellulitis
  - A48.0, H05.011, H05.012, H05.013, H05.019, H60.10, H60.11, H60.12, H60.13, J34.0, J36, J38.3, J38.7, J39.1, K12.2, K13.0, K61.0, K61.1, L03.011, L03.012, L03.019, L03.031, L03.032, L03.039, L03.111, L03.112, L03.113, L03.114, L03.115, L03.116, L03.119, L03.211, L03.212, L03.213, L03.221, L03.311, L03.312, L03.313, L03.314, L03.315, L03.316, L03.317, L03.319, L03.811, L03.818, L03.90, L98.3, N48.22, N49.9, N61.0, N73.0, N73.1, N73.2
- Transferred, eloped, AMA or expired patients are excluded (**V0704**)

**Denominator Exclusions:** None

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Rationale:**

The emergence of community-associated Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) contributed to a significant increase in the incidence and severity of skin and soft tissue infections (SSTIs). A nearly 30% increase in hospital admissions for SSTIs occurred between 2000 and 2004. Annually, over 6 million visits to physician's offices are attributable to SSTIs. From 1993 to 2005, the number of annual emergency department visits for SSTIs increased from 1.2 million to 3.4 million. (Stevens) As a result of the emergence of community-associated MRSA, clinicians increased use of antibiotics targeted at MRSA. According to data from the National Hospital Ambulatory Medical Care Survey (NHAMCS), by 2010, 74% of all antibiotic regimens prescribed at emergency department visits for skin infections included an agent typically active against CA-MRSA. (Pallin)

Despite the drastic increase in use of antibiotics active against CA-MRSA, beta-hemolytic streptococci are still thought to be the predominant cause for non-purulent SSTIs. A large prospective investigation performed in the current era of CA-MRSA found that beta hemolytic streptococci remain the primary cause of diffuse, nonculturable cellulitis. Additionally, the use of antibiotic polypharmacy including vancomycin, if unnecessary, leads to increased drug reactions, risk for renal toxicity, increased medication costs, and emergence of antibiotic resistant bacteria. (Jeng)

In 2014, the Infectious Diseases Society of America (IDSA) updated practice guidelines regarding management of SSTIs and addressed the appropriate use of antibiotics active against CA-MRSA. According to the guidelines, non-purulent cellulitis due to MRSA is uncommon and treatment for MRSA is typically not necessary. The indications for MRSA coverage include penetrating trauma, injection drug use, purulent drainage, evidence of MRSA infection elsewhere, nasal colonization with MRSA, prior MRSA infection, recent hospitalization, recent antibiotic use, markedly impaired host defenses, and patients with SIRS. (Stevens)

Per a multicenter, double-blind, randomized superiority trial conducted by Moran et al., for patients with uncomplicated cellulitis, the addition of an antibiotic for CA-MRSA coverage did not result in higher rates of clinical resolution of cellulitis as compared to coverage for beta-hemolytic streptococcus alone. (Moran)

Despite the emergency of CA-MRSA, beta-hemolytic streptococci remain the predominant cause of non-purulent SSTIs (e.g. cellulitis) and universal treatment for these infections with an antibiotic active against CA-MRSA, such as vancomycin, is not necessary and may contribute to adverse drug reactions, increased medical costs, and the further emergence of antibiotic resistance.

#### **Selected References:**

1. Haran JP, Goulding M, Campion M, et al. Reduction of Inappropriate Antibiotic Use and Improved Outcomes by Implementation of an Algorithm-Based Clinical Guideline for Nonpurulent Skin and Soft Tissue Infections. *Annals of Emergency Medicine*. 2020 July; 76(1): 56-66.
2. Jeng A, Beheshti M, Li J, et al. The Role of Beta-Hemolytic Streptococci in Causing Diffuse, Nonculturable Cellulitis. *Medicine (Baltimore)*. 2010 Jul; 89(4):217-226.
3. Moran GJ, Krishnadasan A, Mower WR, et al. Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis. *JAMA*. 2017 May 23; 317(20): 2088-2096.
4. Pallin DJ, Binder WD, Allen MB, et al. Clinical Trial: Comparative Effectiveness of Cephalexin Plus Trimethoprim-Sulfamethoxazole Versus Cephalexin Alone for Treatment of Uncomplicated Cellulitis: A Randomized Controlled Trial. *Clinical Infectious Diseases*. 2013 June; 56(12): 1754-1762.
5. Shuman EK, Malani PN. Empirical MRSA Coverage for Nonpurulent Cellulitis; Swinging the Pendulum Away From Routine Use. *JAMA*. 2017 May 23/30; 317(20). 2070.
6. Stevens DL, Bisno AL, Chambers HF, et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*. 2014; 59(2):e10-52.

## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #25**

*Referenced Society of Post-Acute and Long-Term Care Medicine's Policy D-14: Promotion of Physician's Orders for Life-Sustaining Treatment Paradigm and the Institute of Medicine of the National Academies: Key Recommendations on Addressing End of Life*

**Measure Title:** Physician's Orders for Life-Sustaining Treatment (POLST) Form

**Inverse Measure:** No

**Measure Description:** Percentage of Patients Aged 65 Years and Older with Physician's Orders for Life-Sustaining Treatment (POLST) Forms Completed

**National Quality Strategy Domain:** Communication and Care Coordination

**Care Setting:** Emergency Department; Hospital; Hospital Outpatient; Hospital Inpatient; Post-Acute Care

**Published Specialty:** Emergency Medicine; Hospitalist; Internal Medicine; Post-Acute Care

**Telehealth?:** Yes

**Type of Measure:** Process, High Priority

**High Priority Type:** Care Coordination

**Meaningful Measure Area:** End of Life Care According to Preferences

**Current Clinical Guideline:** AMDA (The Society of Post-Acute and Long-Term Care Medicine) and the Institute of Medicine (IOM) of the National Academies support and promote the Physician's Orders for Life-Sustaining Treatment Paradigm

**Published Clinical Category:** End of Life Care

**Number of Performance Rates:** 1

**Measure Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Patients with a completed Physician's Orders for Life-Sustaining Treatment (POLST) form

### Definitions:

- Physician's Orders for Life-Sustaining Treatment (POLST) form is defined as a legally recognized, transportable and actionable medical order – intended for seriously ill patients at high risk for mortality – that remains with the patient whether at home, in the hospital, or in a care facility; the form indicates patient-specified medical treatment preferences and is signed by the authorizing

***2024 Measures Specifications***

*Updated 2023.12.20*

- physician, physician assistant (PA), or nurse practitioner (NP)
- The following elements must be present and completed in the Physician's Orders for Life-Sustaining Treatment (POLST) form:
    - Legally recognized decision maker verification
    - Cardiopulmonary Resuscitation (CPR) preferences (e.g., attempt CPR, DNR)
    - Medical Intervention (e.g., full code, comfort measures, limited/selective treatments)
    - Signed by eligible healthcare provider (e.g., physician, PA, or NP)
  - NOTE: The approved version and title of the Physician's Orders for Life-Sustaining Treatment (POLST) form may differ slightly from state to state; variations in forms are acceptable as long as the elements listed above are present

#### Numerator Options

- Performance Met (**VH254**):
  - Existing Physician's Orders for Life-Sustaining Treatment (POLST) form was acknowledged and documented in the medical record OR
  - Physician's Orders for Life-Sustaining Treatment (POLST) form was completed or updated and documented in the medical record OR
  - Documented reason for not acknowledging, completing or updating Physician's Orders for Life-Sustaining Treatment (POLST) form (e.g., patient refuses, patient is unresponsive or does not have capacity to complete, legally recognized decision maker is not present)
- Performance Not Met (**VH255**): Physician's Orders for Life-Sustaining Treatment (POLST) form was not acknowledged, completed or updated, reason not specified.

**Numerator Exclusions:** None

#### **Denominator:**

- Adult patients aged  $\geq 65$  years evaluated by the Eligible Professional in Emergency Services, Inpatient, or Post-Acute Care setting (E/M Codes 99221-99223, 99231-99233, 99234-99236, 99238-99239, 99291-99292, 99304-99310, 99315, 99316 AND Place of Service indicators 02, 10, 19, 21, 22, 23, 31 or 32 OR equivalent in standardized code sets)
- NOTE: This measure is to be submitted a minimum of once per hospitalization for patients seen during the performance period.

**Denominator Exclusions:** None

#### **Rationale:**

For patients and their family caregivers, control over treatment decisions is a high priority with an illness diagnosed as serious and life-limiting. (Singer et al, 1999) The Physician Orders for Life-Sustaining Treatments (POLST) form is designed to supplement and build upon advanced care planning and advanced directives. Unlike advanced directives, which are often generalized and require intermediaries on the patient's behalf (Bomba et al, 2012), the POLST form allows patients to clearly communicate their wishes regarding medical treatment and ensure that those wishes are honored across the care continuum by codifying their advanced directives as portable medical orders. Clinicians are able to focus on treatments desired by patients and avoid treatments that are unwanted by patients. These legally recognized, HIPAA-compliant forms follow the patients wherever they go (e.g., home, skilled nursing facility, acute care facility), and are intended to be

completed for patients who are seriously ill and unlikely to recover (Moss et al., 2008). The POLST form includes key preferences (e.g., DNR status) that can be missed during patient transfers between facilities. The use of the POLST form prevents unwanted hospitalizations, readmissions and invasive medical procedures for patients who are near death. (Lee et al, 2000) AMDA (The Society of Post-Acute and Long-Term Care Medicine) and the Institute of Medicine (IOM) of the National Academies support and promote the Physician's Orders for Life-Sustaining Treatment Paradigm.

In a recent study, POLST completion was 49% in CA nursing home residents, identifying potential opportunity for quality improvement (Jennings).

#### References:

- AMDA – The Society for Post-Acute and Long-Term Care Medicine. Policy D-14: PHYSICIAN ORDERS FOR LIFE-SUSTAINING TREATMENT (POLST). <http://www.paltc.org/amda-white-papers-and-resolution-position-statements/physician-orders-life-sustaining-treatment>. Accessed December 22 2016.
- Basanta WE. (2002). Advance Directives and Life-Sustaining Treatment: A Legal Primer. *Hematology/Oncology Clinics of North America*;16(6):1381-96.
- Bomba PA, Kemp M, Black JS. (2012). POLST: An improvement over traditional advance directives. *Cleveland Clinic Journal of Medicine*;79(7):457-64.
- Dunne PM, Tolle SW, Moss AH, Black JS. (2007). The POLST Paradigm: Respecting the Wishes of Patients and Families. *Annals of Long-Term Care*;15(9):33-40.
- Fromme EK, Zive D, Schmidt TA, Cook JNB, Tolle SW. Association Between Physician Orders for Life-Sustaining Treatment for Scope of Treatment and In-Hospital Death in Oregon. *Journal of the American Geriatrics Society*;62(7)1246-51.
- Hammes B, Rooney BL, Gundrum JD, Hickman SE, Hager N. (2012) The POLST Program: A Retrospective Review of the Demographics of Use and Outcomes in One Community Where Advance Directives Are Prevalent. *Journal of Palliative Medicine*;15(1):77-85.
- Hartle GA, Thimons G, Angelelli J. (2014). *Nursing Research and Practice*, vol. 2014, Article ID 761784, 7 pages. doi:10.1155/2014/761784
- Hickman SE, Nelson CA, Moss AH, Hammes BJ, Terwilliger A, Jackson A, Tolle SW. (2009) Use of the Physician Orders for Life-Sustaining Treatment (POLST) Paradigm Program in the Hospice Setting. *Journal of Palliative Medicine*;12(2):133–41.
- Hickman SE, Nelson CA, Moss AH, Tolle SW, Perrin NA, Hammes BJ. (2011) The Consistency Between Treatments Provided to Nursing Facility Residents and Orders on the Physician Orders for Life-Sustaining Treatment (POLST) Form. *Journal of the American Geriatrics Society*;59(11)2091-99.
- Institute of Medicine (IOM) of the National Academies – Committee on Approaching Death: Addressing Key End of Life Issues. (2014) Key findings and recommendations. *Dying in America: Improving quality and honoring individual preferences near the end of life*. The National Academies Press. <http://www.nationalacademies.org/hmd/~media/Files/Report%20Files/2014/EOL/Key%20Findings%20and%20Recommendations.pdf> Accessed: January 6 2017.
- Kim H, Ersek M, Bradway C, Hickman SE. (2015) Physician Orders for Life-Sustaining Treatment for Nursing Home Residents with Dementia. *Journal of the American Association of Nurse Practitioners*;27(11):606-14.
- Lee MA, Brummel-Smith K, Meyer, J, et al. (2000). Physician Orders for Life-Sustaining Treatment (POLST): Outcomes in a PACE Program. *Journal of the American Geriatrics Society*;48(10):1219-25.
- Moss AH, Ganjoo, J, Sharma S, Gansor J, Senft S, Weaner B, Dalton C, MacKay K, Pellegrino B,

- Anantharaman P, Schmidt R. (2008). Utility of the “Surprise” Question to Identify Dialysis Patients with High Mortality. *Clinical Journal of the American Society of Nephrology*;3(5):1379–84.
- Nisco M, Mittelberger J, Citko J. POLST: An Evidence-Based Tool for Advance Care Planning. <http://www.nphco.org>. Accessed: November 27 2016.
  - Singer PA, Martin DK, Kelner M. (1999). Quality End of Life Care: Patients’ Perspective. *Journal of the American Medical Association*. 281: 163-68.
  - Tolle SW, Tilden VP, Nelson CA, Dunn PM. (1998). A Prospective Study of the Efficacy of the Physician Order Form for Life-sustaining Treatment. *Journal of the American Geriatrics Society*;46(9):1097-102.
  - Vandenbroucke A, Nelson S, Bomba P, Moss AH. (2013) POLST: Advance Care Planning for the Seriously Ill. <http://www.polst.org/>. Accessed: November 27 2016.
  - Jennings, L.A., Zingmond, D., Louie, R. et al. *J GEN INTERN MED* (2016) 31: 1119. <https://doi.org/10.1007/s11606-016-3728-9>



## **H-CPR (Hospitalist – Clinical Performance Registry) Measure #26**

**Measure Title:** Heart Failure (HF): SGLT-2 Inhibitor Therapy for Left Ventricular Systolic Dysfunction (LVSD)

**Inverse Measure:** No

**Measure Description:** Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) less than or equal to 40% who were prescribed SGLT-2 Inhibitor therapy at hospital discharge.

**Care Setting:** Hospital; Hospital Inpatient

**Published Specialty:** Hospitalist, Critical Care

**Telehealth:** Yes

**Type of Measure:** Process

**Clinical Category:** CHF

**Number of Performance Rates:** 1

**Measures Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Patients Who Were Prescribed SGLT-2 Inhibitor Therapy at Time of Hospital Discharge

- **Performance Met (VH275):** SGLT-2 Inhibitor was prescribed at discharge
- **Medical Performance Exclusion (Denominator Exception) (VH276):** Documented medical reason for not prescribing SGLT-2 Inhibitor (e.g., allergy, intolerance, fungal infection, renal failure, DKA)
- **Performance Not Met (VH277):** SGLT-2 Inhibitor was not prescribed at discharge

**Denominator:**

- Any patient aged 18 years and older with a diagnosis of heart failure with a current or prior LVEF  $\leq$  40% evaluated by the Eligible Professional

**AND**

- Diagnosis for heart failure (ICD-10-CM): I11.0, I13.0, I13.2, I50.1, I50.20, I50.21, I50.22, I50.23, I50.30, I50.31, I50.32, I50.33, I50.40, I50.41, I50.42, I50.43, I50.814, I50.82, I50.83, I50.84, I50.89, I50.9

**AND**

- Admitted or Placed in Observation Status (E/M Codes: 99238, 99239 and Place of Service indicators 02 or 21 OR equivalent standardized code sets)
- Transferred, eloped, AMA, or expired patients are excluded (**V0704**)

**Denominator Exclusions:** None

**Rationale:**

Recent studies have shown that a new class of medication, SGLT-2 inhibitors, have been associated with markedly improved outcomes for heart failure patients, lowering rates of both mortality and hospitalization. Thus, in 2022, the American Heart Association, American College of Cardiology, and the Heart Failure Society of America published an updated guideline for the management of heart failure. In this guideline, the guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) was updated to include four medication classes, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors (Heidenreich 2022) as well as Renin-Angiotensin System Inhibition with ACEi or ARB or ARNi and Beta Blockers addressed and measured in existing CQMs.

Per the guideline, patients with type 2 diabetes and either established cardiovascular disease or at high risk for cardiovascular disease should be treated with a SGLT-2 inhibitor to prevent HF-related hospitalizations (Class of Recommendation 1). This recommendation was based on the results of three clinical trials: CANVAS Program, DECLARE-TIMI 58, and EMPA-REG OUTCOME. The CANVAS Program demonstrated that treatment with the SGLT-2 inhibitor canagliflozin was associated with a significantly lower risk of cardiovascular events (composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) compared with placebo. HF-related hospitalizations were also reduced in the canagliflozin treatment group (Neal 2017). The DECLARE-TIMI 58 trial showed that the rate of hospitalization for HF was significantly reduced in patients treated with the SGLT-2 inhibitor dapagliflozin compared with those treated with placebo (Wiviott 2019). The EMPA-REG OUTCOME trial compared patients treated with the SGLT-2 inhibitor empagliflozin and those treated with placebo. In the empagliflozin treatment group, there were significantly lower rates of death from cardiovascular causes, hospitalization for heart failure, and death from any cause (Zinman 2015).

SGLT-2 inhibitors are also recommended for the reduction of HF-related hospitalization and cardiovascular mortality in patients with symptomatic chronic HFrEF, irrespective of the presence of T2D (Class of Recommendation 1). This recommendation was supported by the results from the following clinical trials: DEFINE-HF, DAPA-HF, and EMPEROR-Reduced. The DEFINE-HF trial evaluated patients with HFrEF and found clinically meaningful improvements in HF-related health status in patients treated with the SGLT-2 inhibitor dapagliflozin compared with those treated with placebo. These benefits extended to patients without type 2 diabetes (Nassif 2019). The DAPA-HF trial also evaluated patients with HFrEF. The primary outcomes of worsening HF and cardiovascular death were significantly reduced in patients treated with dapagliflozin compared to those treated with placebo. These benefits were observed regardless of the presence or absence of diabetes (McMurray 2019). The EMPEROR-Reduced trial demonstrated a significant reduction in the primary outcomes of cardiovascular death or hospitalization for HF in patients treated with empagliflozin

compared to those treated with placebo. These benefits were again demonstrated regardless of the presence or absence of diabetes (Packer 2020).

### **Selected References:**

1. Heidenreich PA, Biykem B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145:e895–e1032
2. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019; 381:1995-2008
3. Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction. *Circulation*. 2019;140:1463–1476
4. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med*. 2017; 377:644-657
5. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med*. 2020; 383:1413-1424
6. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 2019; 380:347-357
7. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 2015; 373:2117-2128

## **H-CPR (Emergency – Clinical Performance Registry) Measure #27**

**Measure Title:** Point-of-Care Ultrasound: Evaluation for Pneumothorax after Central Venous Catheter (CVC) Placement

**Inverse Measure:** No

**Measure Description:** Percentage of patients aged 18 years and older who undergo central venous catheter (CVC) insertion for whom Point-of-Care Ultrasound was performed to evaluate for pneumothorax.

**National Quality Strategy Domain:** Patient Safety

**Care Setting:** Emergency Department and Services; Hospital Inpatient; Hospital Outpatient; Hospital

**Published Specialty:** Critical Care, Emergency Medicine

**Telehealth:** No

**Type of Measure:** Process, High Priority

**High Priority Type:** Patient Safety

**Clinical Category:** Preventable Healthcare Harm

**Number of Performance Rates:** 1

**Measures Scoring:** Proportion

**Risk Adjustment:** No

**Submission Pathway:** Traditional MIPS

**Numerator:** Patients Who Received Point-of-Care Ultrasound Evaluation for Pneumothorax after CVC Placement.

- **Performance Met (VH273):** Point-of-Care Ultrasound evaluation for Pneumothorax performed.
- **Medical Performance Exclusion (Denominator Exception) (VH274):** Documented medical reason for not performing Point-of-Care Ultrasound (e.g. no ultrasound machine available, patient refusal)
- **Performance Not Met (VH275):** Point-of-Care Ultrasound evaluation for pneumothorax not performed.

**Denominator:**

- Any patient greater than or equal to 18 years of age who undergoes CVC insertion (limited to internal jugular or subclavian lines) by Eligible Professionals in Emergency Department or Intensive Care Unit Settings (E/M Codes 99221- 99223, 99234-99236, 99281-99285 & 99291-99292 AND Place of Service Indicator: 02, 21 or 23 OR equivalent in standardized code sets).

***2024 Measures Specifications***

*Updated 2023.12.20*

- Transferred, eloped, AMA, or expired patients are excluded **(V0704)**.

**Denominator Exclusions:** None

**Rationale:**

Central venous catheter (CVC) placement is a procedure frequently performed in the Emergency Department (ED) and Intensive Care Unit (ICU) amongst other locations in the hospital. Patients undergoing this procedure are often critically ill, and they require timely interventions and treatment. Pneumothorax is a potentially life-threatening complication of CVC placement. Point-of-Care Ultrasound (POCUS) provides a quick and reliable modality for assessing for this complication, but is **not** meant to replace chest x-ray to confirm placement of the central line. Ultrasound, which is often used to guide placement of the CVC can be readily accessible and can thus reduce the time necessary to identify this complication as opposed to waiting for other imaging modalities such as chest x-ray or CT scan.

Lung ultrasound has been identified as a reliable modality for detecting pneumothorax.<sup>1-5</sup> It has been shown to have greater sensitivity than supine chest x-ray for detecting traumatic pneumothorax.<sup>1,5,6</sup> Soldati, et al. demonstrated that lung ultrasound has accuracy of pneumothorax detection almost as high as that of CT scan, which is the gold standard test.<sup>5</sup> Ultrasound has also been shown to allow differentiation between small, medium and large pneumothoraces with good agreement with CT results.<sup>1</sup> In addition, the time to detection of pneumothorax has been demonstrated to be significantly shorter with US compared to CXR (2.3 +/- 2.9 versus 19.9 +/- 10.3 minutes).<sup>6</sup>

Lung ultrasound is a quick and reliable modality for detecting pneumothorax and should be performed after CVC placement to ensure patient safety.

**Selected References:**

1. Blaivas M, Lyon M, Duggal S. A prospective comparison of supine chest radiography and bedside ultrasound for the diagnosis of traumatic pneumothorax. *Acad Emerg Med.* 2005;12:844–9.
2. DeMasi S, Parker MS, Joyce M, et al. Thoracic point-of-care ultrasound is an accurate diagnostic modality for clinically significant traumatic pneumothorax. *Acad Emerg Med.* 2023; 00: 1- 9.
3. Dulchavsky SA, Schwarz KL, Kirkpatrick AW, Billica RD, Williams DR, Diebel LN, et al. Prospective evaluation of thoracic ultrasound in the detection of pneumothorax. *J Trauma.* 2001;50:201–5.
4. Kirkpatrick AW, Sirois M, Laupland KB, Liu D, Rowan K, Ball CG, et al. Hand-held thoracic sonography for detecting post-traumatic pneumothoraces: The extended focused assessment with sonography for trauma (EFAST) *J Trauma.* 2004;57:288–95.
5. Soldati G, Testa A, Sher S, Pignataro G, La Sala M, Silveri NG. Occult traumatic pneumothorax: Diagnostic accuracy of lung ultrasonography in the emergency department. *Chest.* 2008;133:204–11.
6. Zhang, M., Liu, ZH., Yang, JX. et al. Rapid detection of pneumothorax by ultrasonography in patients with multiple trauma. *Crit Care.* 2006; 10, R112.